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I. General Procedures 
 
General. Unless otherwise noted, all chemicals and reagents were obtained from 
commercial suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further 
purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were taken using a Bruker Prodigy 400 MHz instrument 
and are internally referenced to the residual solvent peak (chloroform). Data for 1H NMR 
are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublets, dt = doublet of 
triplets, ddd = doublet of doublet of doublets), coupling constant (Hz), integration. 
Sonication was performed using a Qsonica Q500 sonicator. High-resolution mass spectra 
were obtained at the California Institute of Technology Mass Spectral Facility. Synthetic 
reactions were monitored using thin layer chromatography (Merck 60 gel plates) using a 
UV-lamp for visualization. Substrates were purchased from commercial suppliers. 
 
Chromatography. Analytical reversed-phase high-performance liquid 
chromatography (HPLC) was carried out using an Agilent 1200 series instrument and a 
Kromasil 100 C18 column (4.6 × 50 mm, 5 µm) with water and acetonitrile as the mobile 
phase and visualization at 210 nm for library screening. Analytical normal-phase HPLC 
was carried out using an Agilent 1200 series instrument and chiral columns Chiralpak IC 
(4.6 mm x 25 cm), IA (4.6 mm x 25 cm), AS-H (4.6 mm x 25 cm) and OJ-H (4.6 mm x 25 
cm) with n-hexane and isopropanol as the mobile phase and visualization at 210 nm for 
chiral separation. Gas chromatography (GC) analyses were carried out using an Agilent 
7820A or Shimadzu GC-17A gas chromatograph, FID detector, and a J&W HP-5 column 
(30 m × 0.32 mm, 0.25 μm film). Gas chromatography-mass spectrometry (GC-MS) 
analyses were carried out using a Shimadzu GCMS-QP2010SE system and J&W HP-5m 
column. Semi-preparative HPLC was performed using an Agilent XDB-C18 column (9.4 
x 250 mm, 5 µm) with water and acetonitrile as the mobile phase.  
 
Cloning and site-saturation mutagenesis. pET22b(+) containing a C-terminal 6x-
His tag was used as a cloning and expression vector for all enzymes described in this study. 
Site-saturation mutagenesis was performed using a modified QuikChangeTM mutagenesis 
protocol (40). The PCR products were digested with DpnI, gel purified, and the gaps were 
repaired using Gibson MixTM (41). The ligation mixture was used to directly transform E. 
coli strain BL21 E. cloni® (Lucigen). Cells were grown using Luria-Bertani medium (LB) 
or Hyperbroth (AthenaES) (HB) with 0.1 mg/mL ampicillin (LBamp or HBamp). Primer 
sequences are available upon request. Electrocompetent E. coli cells were prepared 
following the protocol of Sambrook et al. (42). T5 exonuclease, Phusion polymerase, and 
Taq ligase were purchased from New England Biolabs (NEB, Ipswich, MA). M9-N 
minimal medium (abbreviated as M9-N buffer; pH 7.4) was used as a buffering system for 
whole cells, lysates, and purified proteins, unless otherwise specified. M9-N buffer was 
used without a carbon source; it contains 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM 
NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2. 
 
Determination of hemeprotein concentration. A solution of sodium dithionite (10 
mg/mL) was prepared in M9-N buffer. Separately, a solution of 1 M NaOH (0.4 mL) was 
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mixed with pyridine (1 mL), followed by centrifugation (10,000 g, 30 s) to separate the 
excess aqueous layer gave a pyridine-NaOH solution. To a cuvette containing 700 μL 
protein solution (purified protein or lysate) in M9-N buffer, 50 μL of dithionite solution 
(0.1 M in M9-N) and 250 μL pyridine-NaOH solution were added. The cuvette was sealed 
with Parafilm, and the UV-Vis spectrum of the reduced FeII state was recorded 
immediately. To another cuvette containing 700 μL protein solution (purified protein or 
lysate) in M9-N buffer, 50 μL of potassium ferricyanide (0.1 M in M9-N) and 250 μL 
pyridine-NaOH solution were added. The cuvette was sealed with Parafilm, and the UV-
Vis spectrum of the oxidized FeIII state was recorded immediately. Hemeprotein 
concentration was determined using ε557[Re]-540[Ox] = 23.98 mM-1cm-1 (43). Cytochrome c 
concentration is measured using a different procedure, reported previously (44).  
 
Expression of P450 and P411 proteins. E. coli BL21 E. cloni® cells carrying a 
plasmid encoding a P450 or P411 variant were grown overnight in 5 mL LBamp (37 ºC, 250 
rpm). The pre-culture was used to inoculate 45 mL of HBamp in a 125 mL Erlenmeyer flask; 
this culture was incubated at 37 ºC, 220 rpm for 2 h and 15 min. Cultures were then cooled 
on ice (20 min), and expression was induced with 0.5 mM IPTG and 1.0 mM 5-
aminolevulinic acid (final concentrations). Expression was conducted at room temperature 
(23 ºC), at 130 rpm, for 18 – 22 h. Cultures were then centrifuged (4,500 g, 5 min, 4 ºC), 
and the pellets were resuspended to an OD600 of 30 in M9-N minimal medium (no 
nitrogen). Aliquots of the cell suspension (4 mL) were used to determine the P450 and 
P411 expression level after lysis by sonication. The expression level in OD600 = 30 lysates 
is typically in the range 8 ‒ 12 μM for P450s, 1 ‒ 4 μM for P450 H*, and 2 ‒ 7 μM for 
P411s. 
The same procedure was used for expression of globin proteins, except using 1 mL 
LBamp pre-culture to inoculate 49 mL of HBamp. The expression of cytochrome c variants 
requires an extra maturation plasmid pEC86 in E. coli BL21 E. cloni® cells and follows a 
procedure described previously (44). 
 
Biotransformations. The cell suspension in M9-N (with a certain OD600) was 
degassed by sparging with argon in sealed vials or flasks for 30 min. Separately, a glucose 
solution (250 mM in M9-N) was degassed by sparging with argon for 30 minutes. All 
solutions were uncapped and transferred into an anaerobic chamber. Resuspended cells 
(340 µL) were added to 2 mL vials, followed by glucose (40 µL, 250 mM in M9-N), alkyne 
(10 µL of an EtOH stock), and EDA (10 µL of an EtOH stock). Final concentrations were 
typically 10.0 – 20.0 mM alkyne, 10.0 – 20.0 mM EDA (alkyne: EDA = 1: 1), and 25 mM 
glucose; final reaction volume was 400 µL. The vials were sealed, removed from the 
anaerobic chamber, and shaken at room temperature and 560 rpm for 6 h. After the reaction 
was completed, internal standard 1,3,5-trimethoxybenzene (20 μL of 20 mM stock solution 
in toluene) was added to the reaction vial followed by mixed solvent (cyclohexane / ethyl 
acetate = 1 : 1, 1.0 mL). The mixture was transferred to a 1.5 mL microcentrifuge tube, and 
then subjected to vortex (15 s × 3) and centrifugation (14,000 rpm, 5 min) to completely 
separate the organic and aqueous layers. A sample of the organic layer (0.8 mL) was 
transferred to a vial for GC analysis. The procedure for preparative-scale enzymatic 
reactions is outlined in detail (See Section VIII and IX).  
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Reaction screening in 96-well plate format. Single-site-saturation libraries were 
generated employing the “22c-trick” method (40) and screened in one 96-well plate; 
double-site-saturation libraries were generated using the same method to target two 
different sites; these were screened in three 96-well plates. E. coli libraries were cultured 
in LBamp (300 µL/well) at 37 ºC, 250 rpm and 80% relative humidity overnight. HBamp (950 
µL/well) was inoculated with the pre-culture (50 µL/well) and incubated at 37 ºC, 250 rpm, 
80% humidity for 2.5 h. The plates were cooled on ice for 30 minutes, and expression was 
induced with 0.5 mM IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). 
Expression was conducted at 20 ºC and 200 rpm for 18 – 22 h. The cells were pelleted 
(4,500 g, 5 min, 4 ºC) and resuspended with M9-N buffer (340 µL/well) and D-glucose 
solution (40 µL/well, in M9-N). The 96-well plate was then transferred to an anaerobic 
chamber. In the anaerobic chamber, alkyne (10 µL/well, 400 mM in EtOH) and EDA (10 
µL/well, 400 mM in EtOH). The plate was sealed with an aluminum foil, removed from 
the anaerobic chamber, and shaken at 560 rpm. See below for reaction workup protocol: 
Bicyclobutane formation screening. After 16 h, the seal was removed and mixed 
solvent (cyclohexane / ethyl acetate = 1 : 1, 600 µL/well) and internal standard 1,3,5-
trimethoxybenzene (20 µL/well of a toluene stock) were added. The plate was tightly 
sealed with a reusable silicone mat, vortexed (15 s × 3) and centrifuged (4,500 g, 5 min) to 
completely separate the organic and aqueous layers. The organic layers (200 µL/well) were 
transferred to 300 µL vial inserts, which were then placed in 2 mL vials labeled with 
corresponding wells in the plate for GC or GC-MS analysis (a 2.5-min/run method was 
used for screening, see Section IV). 
Cyclopropene formation screening. After 16 h, the seal was removed and acetonitrile 
(580 µL/well) and internal standard ethyl phenylacetate (PhEA, 20 mM in acetonitrile, 20 
µL/well) were added. The plate was tightly sealed with a reusable silicone mat, vortexed 
(15 s × 3) and centrifuged (4,500 g, 5 min). The supernatant (200 µL/well) was filtered 
through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well plate for HPLC 
analysis (a 1.7-min/run method was used for screening, see Section V).  
 
Protein purification. E. coli BL21 E. cloni® cells carrying a plasmid encoding a P411 
variant were grown overnight in 105 mL LBamp (37 ºC, 250 rpm). HBamp (1 L) in a 2.8 L 
flask was inoculated with 100 mL of the pre-culture and incubated at 37 ºC and 240 rpm 
for 2 h and 15 min. Cultures were then cooled on ice (30 min) and induced with 0.5 mM 
IPTG and 1.0 mM 5-aminolevulinic acid (final concentrations). Expression was conducted 
at 20 ºC, 130 rpm, for 20 h. Cultures were then centrifuged (4,500 g, 8 min, 4 ºC) and the 
cell pellets frozen at –20 ºC. For purification, frozen cells from two such cultures were 
resuspended in buffer A (25 mM Tris-HCl buffer, 20 mM imidazole, 100 mM NaCl, pH 
7.5, 4 mL/g of cell wet weight), loaded with hemin (1 mg/gram wet cell weight) and 
powdered DNaseI, and lysed by sonication. To pellet cell debris, lysates were centrifuged 
(20,000 x g, 20 min, 4 ºC). Proteins were expressed in a construct containing a 6x-His tag 
and purified using a nickel NTA column (1 mL HisTrap HP, GE Healthcare, Piscataway, 
NJ) using an AKTA or AKTAxpress purifier FPLC system (GE healthcare). P411 enzymes 
were eluted with a linear gradient from 100% buffer A to 100% buffer B (25 mM tris, 300 
mM imidazole, 100 mM NaCl, pH 7.5) over 10 column volumes. Proteins were then 
pooled, concentrated, and subjected to three exchanges of phosphate buffer (0.1 M KPi, 
pH 8.0) using centrifugal filters (10 kDa molecular weight cut-off, Amicon Ultra, Merck 
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Millipore) to remove excess salt and imidazole. Concentrated proteins were aliquoted, flash 
frozen on powdered dry ice, and stored at –80 or –20 ºC. 
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II. Supporting Tables and Figures 
 
 
Figure S1. Ring structures and calculated ring strains (1, 2) 
The 4-membered carbocycles, bicyclo[1.1.0]but-1(3)-ene and tricyclo[1.1.0.02,4]butane 
(tetrahedrane) (with calculated strain energy) have never been isolated, although their 
derivatives with bulky substituents might be synthesized in stable form under certain 
conditions (1). 
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Figure S2. Synthetic methods for forming bicyclobutanes (3, 11-15, 45-61) 
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Figure S3. Examples of three-membered ring-containing natural products (21-23, 62-66)  
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III. Screening of Different Catalysts for Bicyclobutane Formation 
Table S1. Screening different catalysts for bicyclobutane formation 
 
 (Abbreviations: Ac = acetyl, Piv = pivaloyl, DOSP = N-(p-dodecylphenylsulfonyl) 
prolinato, esp = α,α,α′,α′-tetramethyl-1,3-benzenedipropionate, Tf = trifluoromethane-
sulfonyl, NHC = 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene.) 
Table S2. Information of hemeprotein variants 
Name Description Mutations 
P450-WT 
P450BM3-wild type 
(CYP102A1) (67) 
- 
P450-CIS P450BM3-CIS variant (27) 
V78A, F87V, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
T268A, A290V, L353V, I366V, 
E442K (relative to P450-WT) 
P411-CIS P411BM3-CIS variant (32) C400S (relative to P450-CIS) 
P450-CIS H* P450BM3-CIS H* variant (68) C400H (relative to P450-CIS) 
P411-S1 P411BM3-CIS S1 variant (32) T438S (relative to P411-CIS) 
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P411-“I263F” 
P411BM3-CIS “I263F” variant 
(69) 
I263F (relative to P411-S1) 
P411-P2 P411BM3-CIS P2 variant (28) 
I263F, A328V (relative to P411-
S1) 
P411-P3 P411BM3-CIS P3 variant (28) 
V87A, I263F, A328V (relative to 
P411-S1) 
P411-P4 P411BM3-CIS P4 variant (28) 
V87A, I263F, A268G, A328V 
(relative to P411-S1) 
P411-“A82L” 
P411BM3-CIS “A82L” variant 
(28) 
A82L, V87A, I263F, A268G, 
A328V (relative to P411-S1) 
P411-E10 P411BM3-CIS E10 variant (29) 
A78V, A82L, V87A, I263L, 
A268G, A328V (relative to P411-
S1) 
Rma cyt c 
Rhodothermus marinus 
cytochrome c wild-type (44) 
- 
Rma cyt c 
TDE 
Rhodothermus marinus 
cytochrome c TDE variant (44) 
V75T, M100D, M103E (relative to 
Rma cyt c) 
myoglobin 
Sperm whale myoglobin-wild 
type (70) 
- 
myoglobin 
VA 
Sperm whale myoglobin-VA 
variant (70) 
H64V, V68A (relative to 
Myoglobin) 
Rma NOD 
Q52V 
Rhodothermus marinus nitric 
oxide dioxygenase Q52V variant  
Q52V (relative to Rma NOD-wild 
type) 
Ape pgb 
Y60G 
Aeropyrum pernix protoglobin 
Y60G variant 
Y60G (relative to Ape pgb wild-
type) 
 
General procedure for testing transition metal catalysts for designed carbene transfer 
to alkyne (Table S1):  
To an 8 mL vial were added phenyl acetylene (0.1 mmol), catalyst (Rh - 1 mol%; Cu 
- 10 mol%) and DCM or cyclohexane (2 mL). The vial was cooled to –78 °C. EDA (0.2 
mmol in 0.5 mL corresponding organic solvent) was added through a syringe pump over 1 
h. The reaction was stirred at −78 °C for 6 h and then slowly warmed to room temperature 
over another 6 h. The reaction mixture (0.5 mL) was filtered through a 2 cm-height silica 
gel and washed with DCM (1 mL). The filtrate was used for GC-MS analysis. 
 
The procedure for testing hemeproteins follows that described in biotranformations (See 
Section I) using E. coli expressing corresponding hemeprotein variant as whole-cell 
catalyst (OD600 = 30). For testing heme (± BSA), 0.5 mM stock of heme (± BSA, 0.75 
mg/mL) in M9-N (340 μL) and Na2S2O4 (40 μL, 10 mM in M9-N) was used instead of cell 
suspension and glucose stock. (BSA = bovine serum albumin). 
 
2-Ethoxy-5-phenylfuran (3b) 
 
1H NMR (400 MHz, Benzene-d6) δ 7.58 (dd, J = 8.3, 1.3 Hz, 2H), 7.14 – 
7.09 (m, 2H), 6.97 (tt, J = 7.4, 1.3 Hz, 1H), 6.37 (d, J = 3.3 Hz, 1H), 5.02 
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(d, J = 3.3 Hz, 1H), 3.59 (q, J = 7.0 Hz, 2H), 0.98 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, 
C6D6) δ 161.79, 145.08, 132.15, 129.52, 127.04, 123.49, 107.28, 83.71, 67.27, 15.07. MS 
(EI) m/z: 188 (M+∙); calc. for C12H12O2: 188. 
 
Ethyl 2-phenyl-3-(trimethylsilyl)cycloprop-2-ene-1-carboxylate (3c) 
 
The synthesis of 3c follows a reported procedure (71). 1H NMR (400 MHz, 
CDCl3) δ 7.61 – 7.52 (m, 2H), 7.48 – 7.36 (m, 3H), 4.25 – 4.06 (m, 2H), 
2.40 (s, 1H), 1.25 (t, J = 7.1 Hz, 3H), 0.34 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 176.13, 129.79, 129.52, 128.65, 127.56, 123.95, 108.00, 60.00, 
20.60, 14.37, –1.43. MS (EI) m/z: 260 (M+∙); calc. for C15H20O2Si: 260. 
 
Ethyl 2-phenylcycloprop-2-ene-1-carboxylate (3a) 
 
To a 20 mL vial were added 3c (20.8 mg, 0.08 mmol) and THF (2 mL). 
And then tetrabutylammonium fluoride (TBAF, 1M in THF, 120 μL) was 
added to the solution. The reaction was stirred at room temperature for 3 
min before it was condensed under reduced pressure (3 min). Quick purification (within 5 
min) of the crude product by silica column chromatography with hexane / ethyl acetate 
(10:1) afforded 3a. 3a was used for qualitative GC-MS analysis. (Note: 3a is highly 
unstable. It was completely decomposed under deprotection condition after 30 min. 
Purification step needs to be very quick. After column purification, it is better to leave 3a 
in the hexane/ ethyl acetate eluent rather than concentrate it under reduced pressure. 3a can 
stay for hours in a solution form, but for less than 30 min in pure form.) MS (EI) m/z: 188 
(M+∙); calc. for C12H12O2: 188. 
GC-MS traces: 
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Figure S4. GC-MS traces of cyclopropene 3a, furan 3b and bicyclobutane 2a 
GC-MS conditions for 3a: 90 °C, isothermal for 2.0 min; 90 °C to 300 °C, 40 °C/min 
gradient, 5.25 min; 300 °C, isothermal for 2 min. 
GC-MS conditions for 3b: 90 °C, isothermal for 2.0 min; 90 °C to 300 °C, 40 °C/min 
gradient, 5.25 min; 300 °C, isothermal for 4 min. 
GC-MS conditions for 2a: 90 °C, isothermal for 2.0 min; 90 °C to 300 °C, 40 °C/min 
gradient, 5.25 min; 300 °C, isothermal for 4 min. 
Note: High temperature (> 250 °C) of the GC might degrade the bicyclobutane to some 
extent, resulting in a broad peak and another small peak (the whole signal is from pure 
bicyclobutane 2a). The signal is nonetheless suitable for quantitative analysis. 
 
Time course of furan formation with P411-S1 I263W variant: 
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Figure S5. Time course of furan formation with P411-S1 I263W variant 
Note: Reactions were set up in parallel according to the procedure in biotranformations 
(See Section I) using whole-cell catalyst (OD600 = 30). The reactions were quenched at 
certain time points and analyzed by GC-MS. Every data point (average of two reaction) is 
the peak area of cyclopropene 3a or furan 3b divided by that of internal standard on GC-
MS. Cyene = cyclopropene. 
 
GC-MS trace of furan formation with P411-S1 I263W variant under standard 
conditions: 
  
Figure S6. GC-MS trace of furan formation with P411-S1 I263W variant 
GC-MS conditions: 90 °C, isothermal for 1.5 min; 90 °C to 300 °C, 40 °C/min gradient, 
5.25 min; 300 °C, isothermal for 2 min.  
 
Time course of bicyclobutane formation with P411 E10 variant: 
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Figure S7. Time course of bicyclobutane formation with P411-E10 variant 
Note: Reactions were set up in parallel according to the procedure in biotranformations 
(See Section I) using whole-cell catalyst (OD600 = 30). The reactions were quenched at 
certain time points and analyzed by GC-MS. Every data point (average of two reaction) is 
the peak area of cyclopropene 3a or bicyclobutane 2a divided by that of the internal 
standard on GC-MS. Bicyane = bicyclobutane. 
 
GC-MS trace of bicyclobutane formation with P411-E10 variant under standard 
conditions: 
 
Figure S8. GC-MS trace of bicyclobutane formation with P411-E10 variant 
GC-MS conditions: 90 °C, isothermal for 2.0 min; 90 °C to 300 °C, 40 °C/min gradient, 
5.25 min; 300 °C, isothermal for 4 min. 
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IV. Directed Evolution of P411-E10 for Bicyclobutane Formation 
 
 
Figure S9. Evolutionary trajectory for bicyclobutane formation 
 
Table S3. P411-S1 variants for bicyclobutane formation 
P411-S1 variants TTN 
P4 80 ± 10 
“A82L” 280 ± 20 
E10 530 ± 20 
E10 V78Y 800 ± 30 
E10 V78F 1030 ± 60 
E10 S438A 1400 ± 50 
E10 V78Y S438A 1560 ± 70 
E10 V78F S438A 1880 ± 80 
 
Note: Analytical reactions were set up in quadruplicate according to the procedure in 
biotranformations (Section I) using whole-cell catalyst and analyzed by GC using the 
standard calibration curve of 2a (see Section VIII). The TTNs were obtained for OD600=30 
for P4, A82L and E10 variants, OD600=15 for E10 V78Y and E10 V78F variants, and 
OD600=10 for E10 S438A, E10 V78Y S438A and E10 V78F S438A variants. TTNs 
reported are the average of biological duplicates. Each biological set contains four 
experiments. The errors in all tables are standard deviations. 
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Table S4. Mutations in related P411-E10 variants 
Name Description Mutations relative to P450-WT 
P4 P411BM3-CIS P4 variant (28) 
V78A, F87A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, 
E442K 
“A82L” 
P411BM3-CIS “A82L” variant 
(28) 
V78A, A82L, F87A, P142S, 
T175I, A184V, S226R, H236Q, 
E252G, I263F, T268G, A290V, 
A328V, L353V, I366V, C400S, 
T438S, E442K 
E10 P411BM3-CIS E10 variant (29) 
A82L, F87A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263L, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, 
E442K 
E10 V78Y P411BM3-CIS E10 V78Y 
V78Y, A82L, F87A, P142S, 
T175I, A184V, S226R, H236Q, 
E252G, I263L, T268G, A290V, 
A328V, L353V, I366V, C400S, 
T438S, E442K 
E10 V78F P411BM3-CIS E10 V78F 
V78F, A82L, F87A, P142S, 
T175I, A184V, S226R, H236Q, 
E252G, I263L, T268G, A290V, 
A328V, L353V, I366V, C400S, 
T438S, E442K 
E10 S438A P411BM3-CIS E10 S438A 
A82L, F87A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263L, T268G, A290V, A328V, 
L353V, I366V, C400S, T438A, 
E442K 
E10 V78Y 
S438A 
P411BM3-CIS E10 V78Y S438A 
V78Y, A82L, F87A, P142S, 
T175I, A184V, S226R, H236Q, 
E252G, I263L, T268G, A290V, 
A328V, L353V, I366V, C400S, 
T438A,  E442K 
E10 V78F 
S438A 
P411BM3-CIS E10 V78F S438A 
V78F, A82L, F87A, P142S, 
T175I, A184V, S226R, H236Q, 
E252G, I263L, T268G, A290V, 
A328V, L353V, I366V, C400S, 
T438A, E442K 
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V. Directed Evolution of P411-P4 for Cyclopropene Formation 
 
Figure S10. Sites targeted in the evolution of P411-P4 for (S)-cyclopropene formation 
(PDB: 4WG2, P411-“I263F” (69)) 
 
 
Figure S11. Evolutionary trajectory for the formation of cyclopropene (S)-6a 
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Table S5. P411-P4 variants for the formation of cyclopropene (S)-6a 
P411-P4 variant TTN er 
P4 260 ± 30 95.5: 4.5 
P4 A87F (K1) 290 ± 20 3.0: 97.0 
K1 F261G T327P (K3) 660 ± 40 2.6: 97.4 
K3 S72W L437F (K5) 1100 ± 120 2.1: 97.9 
K5 T269L (K6) 1280 ± 80 1.9: 98.1 
K6 A78S A330V (K8) 1900 ± 200 0.55: 99.45 
K8 L188C T436M (K10) 3300 ± 180 0.45: 99.55 
 
Note: Analytical reactions were set up in quadruplicate according to the procedure in 
biotranformations (Section I) using whole-cell catalyst and analyzed by GC using the 
standard calibration curve of 6a (see Section IX). The TTNs were obtained using 
OD600=60 for P4 and K1 variants, OD600=30 for K3, K5 and K6 variants, and OD600=15 
for K8 and K10 variants. TTNs reported are the average of biological duplicates. Each 
biological set contains four experiments. The errors in all tables are standard deviations. 
 
Table S6. Mutations in related P411-P4 variants 
Name Description Mutations relative to P450-WT 
P4 P411BM3-CIS P4 variant (28) 
V78A, F87A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, 
E442K 
K1 P411BM3-CIS K1 variant 
V78A, P142S, T175I, A184V, 
S226R, H236Q, E252G, I263F, 
T268G, A290V, A328V, L353V, 
I366V, C400S, T438S, E442K 
K3 P411BM3-CIS K3 variant  
V78A, P142S, T175I, A184V, 
S226R, H236Q, E252G, F261G, 
I263F, T268G, A290V, T327P, 
A328V, L353V, I366V, C400S, 
T438S, E442K 
K5 P411BM3-CIS K5 variant 
S72W, V78A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
F261G, I263F, T268G, A290V, 
T327P, A328V, L353V, I366V, 
C400S, L437F, T438S, E442K 
K6 P411BM3-CIS K6 variant 
S72W, V78A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
F261G, I263F, T268G, T269L, 
A290V, T327P, A328V, L353V, 
I366V, C400S, L437F, T438S, 
E442K 
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K8 P411BM3-CIS K8 variant 
S72W, V78S, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
F261G, I263F, T268G, T269L, 
A290V, T327P, A328V, A330V, 
L353V, I366V, C400S, L437F, 
T438S, E442K 
K10 P411BM3-CIS K10 variant 
S72W, V78S, P142S, T175I, 
A184V, L188C, S226R, H236Q, 
E252G, F261G, I263F, T268G, 
T269L, A290V, T327P, A328V, 
A330V, L353V, I366V, C400S, 
T436M, L437F, T438S, E442K 
 
 
 
Figure S12. Sites targeted in the directed evolution of P411-P4 for (R)-cyclopropene 
formation (PDB: 4WG2, P411-“I263F” (69)) 
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Figure S13. Evolutionary trajectory for the formation of cyclopropene (R)-6a 
 
Table S7. P411-P4 variants for the formation of cyclopropene (R)-6a 
P411-P4 variant TTN er 
P4 260 ± 30 95.5: 4.5 
P4 A87W (C1) 240 ± 40 97.1: 2.9 
K1 L437G (C2) 1400 ± 100 99.35: 0.65 
C2 V328Y (C3) 1600 ± 120 99.80: 0.20 
C3 T327V (C4) 1700 ± 100 99.90: 0.10 
C4 F261M T436H (C6) 2500 ± 140 99.95: 0.05 
 
Note: Analytical reactions were set up in quadruplicate according to the procedure in 
biotranformations (Section I) using whole-cell catalyst and analyzed by GC using the 
standard calibration curve of 6a (see Section IX). The TTNs were obtained using 
OD600=60 for P4 and C1 variants, OD600=30 for C2, C3 and C4 variants, and OD600=15 
for C6 variant. TTNs reported are the average of four experiments. TTNs reported are the 
average of biological duplicates. Each biological set contains four experiments. The errors 
in all tables are standard deviations. 
 
Table S8. Mutations in related P411-P4 variants 
Name Description Mutations relative to P450-WT 
P4 P411BM3-CIS P4 variant (28) 
V78A, F87A, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
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I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, 
E442K 
C1 P411BM3-CIS C1 variant 
V78A, F87W, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, T438S, 
E442K 
C2 P411BM3-CIS C2 variant  
V78A, F87W, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, 
L353V, I366V, C400S, L437G, 
T438S, E442K 
C3 P411BM3-CIS C3 variant 
V78A, F87W, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328Y, 
L353V, I366V, C400S, L437G, 
T438S, E442K 
C4 P411BM3-CIS C4 variant 
V78A, F87W, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, T327V, 
A328Y, L353V, I366V, C400S, 
L437G, T438S, E442K 
C6 P411BM3-CIS C6 variant 
V78A, F87W, P142S, T175I, 
A184V, S226R, H236Q, E252G, 
F261M, I263F, T268G, A290V, 
T327V, A328Y, L353V, I366V, 
C400S, T436H, L437G, T438S, 
E442K 
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VI. Substrate Synthesis and Characterization  
Commercially available substrates were used as received: all aromatic alkynes (1a‒
1m) (Sigma-Aldrich, Alfa-Aesar and Ark Pharm), aliphatic alkynes (5a‒5c, 5g, 5j, 5k, 5m, 
and 5n) (Sigma-Aldrich, Alfa-Aesar and Ark Pharm), ethyl 2-diazoacetate (Sigma-
Aldrich). 
 
 
Figure S14. Alkyne substrates 
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Oct-7-yn-1-yl cyclobutanecarboxylate (5d) 
 
In a 100 mL round-bottom flask, oct-7-yn-1-ol (0.631 g, 
5.0 mmol), triethylamine (0.9 mL, 1.3 equiv.) and N,N-
dimethylpyridin-4-amine (DMAP, 61 mg, 10 mol%) in 
dry DCM (20 mL) was cooled to 0 °C. A solution of cyclobutanecarbonyl chloride (0.711 
g, 6.0 mmol) in dry DCM (5 mL) was added dropwise slowly over 5 min. The reaction was 
allowed to warm to room temperature and stirred for 8 hours. The reaction mixture was 
diluted with DCM (20 mL) and washed with water (20 mL) and brine (20 mL), dried over 
MgSO4, and then concentrated under reduced pressure. The crude product was purified by 
silica column chromatography with hexane / ethyl acetate (20:1) to afford 5d (1.02 g, 98%). 
1H NMR (400 MHz, CDCl3) δ 4.06 (t, J = 6.7 Hz, 2H), 3.12 (pd, J = 8.5, 1.0 Hz, 1H), 2.34 
– 2.13 (m, 6H), 2.04 – 1.83 (m, 3H), 1.69 – 1.59 (m, 2H), 1.57 – 1.48 (m, 2H), 1.47 – 1.32 
(m, 4H). 13C NMR (101 MHz, CDCl3) δ 175.62, 84.51, 68.25, 64.28, 38.17, 28.54, 28.34, 
28.32, 25.45, 25.28, 18.43, 18.33. HRMS (FAB) m/z: 209.1548 (M + H+); calc. for 
C13H21O2: 209.1542. 
 
2-(Hept-6-yn-1-yl)-1,3-dioxolane (5e) 
 
In a 250 mL round-bottom flask, DMSO (1.95 g, 25.0 mmol) 
was dissolved in dry DCM (40 mL) and then cooled to ‒78 °C 
under argon. A solution of oxalyl dichloride (2.6 mL, 30.0 
mmol) in dry DCM (10 mL) was added dropwise slowly over 10 min. After the mixture 
was stirred at ‒78 °C for 1 h, a solution of oct-7-yn-1-ol (0.631 g, 5.0 mmol) in dry DCM 
(10 mL) was added dropwise slowly over 10 min. The resulting mixture was maintained at 
‒78 °C for another 2 h before the dropwise addition of triethylamine (7.0 mL, 50.0 mmol) 
in dry DCM (10 mL). The reaction was then allowed to warm to room temperature over 1 
h and stirred for another 2 h. The reaction mixture was diluted with DCM (30 mL) and 
washed with HCl (10%, 50 mL), NaHCO3 (50 mL, sat. aq.), and brine (50 mL), dried over 
MgSO4, and then concentrated under reduced pressure (100 torr). The crude product 
mixture was used for the next step without further purification.The crude product was 
dissolved in benzene (50 mL) in a 100 mL round-bottom flask. Ethylene glycol (0.465 g, 
7.5 mmol) and TsOH (130 mg, 0.075 mmol) were added. The solution was heated up to a 
refluxing temperature, 90 °C, and maintained for 2 h. After removal of benzene under 
reduced pressure, the crude product was purified by silica column chromatography with 
hexane / ether (20:1 to 15:1) to afford 5e (0.675 g, 80%). 1H NMR (400 MHz, CDCl3) δ 
4.85 (t, J = 4.8 Hz, 1H), 4.01 – 3.91 (m, 2H), 3.90 – 3.79 (m, 2H), 2.19 (td, J = 7.0, 2.6 Hz, 
2H), 1.93 (t, J = 2.7 Hz, 1H), 1.70 – 1.61 (m, 2H), 1.59 – 1.51 (m, 2H), 1.49 – 1.39 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 104.66, 84.73, 68.32, 64.99, 33.89, 28.78, 28.53, 
23.69, 18.45. HRMS (FAB) m/z: 167.1067 ((M + H+) ‒ H2); calc. for C10H15O2: 167.1072. 
 
5-Isopropoxypent-1-yne (5f) 
 
In a 100 mL round-bottom flask, pent-4-yn-1-ol (0.841 g, 10.0 
mmol), triethylamine (1.8 mL, 1.3 equiv.) and DMAP (122 mg, 10 
mol%) in dry DCM (50 mL) was cooled to 0 °C. 4-
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Methylbenzenesulfonyl chloride (TsCl, 2.10 g, 11.0 mmol) was added portion-wise. The 
reaction was allowed to warm to room temperature and stirred for 6 hours. The reaction 
mixture was diluted with DCM (30 mL) and washed with water (20 mL) and brine (20 
mL), dried over MgSO4, and then concentrated under reduced pressure. The crude product 
was purified by silica column chromatography with hexane: ethyl acetate (4:1) to afford 
pent-4-yn-1-yl 4-methylbenzenesulfonate (2.35 g, 99%).  
 Isopropanol (0.361 g, 6.0 mmol) and tetrabutylammonium bromide (161 mg, 0.5 
mmol) were dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH (60%, 
240 mg, 6.0 mmol) was added portion-wise to the solution. The resulting mixture was 
stirred at 0 °C for 1 h before the dropwise addition of pent-4-yn-1-yl 4-
methylbenzenesulfonate (1.19 g, 5.0 mmol) in anhydrous DMF (10 mL). The reaction was 
allowed to warm to room temperature and stirred for 4 hours. The reaction mixture was 
quenched with NH4Cl (20 mL, sat. aq.) and the product was extracted with Et2O (30 mL × 
3). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over 
MgSO4, and then concentrated under reduced pressure (200 torr). The crude product was 
purified by silica column chromatography with pentane / ether (10: 1) to afford 5f (0.597 
g, 95%).  
 
4-((Oct-7-yn-1-yloxy)methyl)tetrahydro-2H-pyran (5h) 
 
In a 500 mL round-bottom flask, oct-7-yn-1-ol (6.31 g, 
50.0 mmol), triethylamine (9.1 mL, 1.3 equiv.) and 
DMAP (609 mg, 10 mol%) in dry DCM (200 mL) was 
cooled to 0 °C. TsCl (10.50 g, 55.0 mmol) was added portion-wise. The reaction was 
allowed to warm to room temperature and stirred for 6 hours. The reaction mixture was 
diluted with DCM (100 mL) and washed with water (200 mL) and brine (200 mL), dried 
over MgSO4, and then concentrated under reduced pressure. The crude product was 
purified by silica column chromatography with hexane: ethyl acetate (10:1) to afford oct-
7-yn-1-yl 4-methylbenzenesulfonate (13.29 g, 95%). 
 In a 100 mL round-bottom flask, (tetrahydro-2H-pyran-4-yl)methanol (0.697 g, 6.0 
mmol) and tetrabutylammonium bromide (161 mg, 0.5 mmol) were dissolved in anhydrous 
DMF (50 mL) and then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) was added portion-
wise to the solution. The resulting mixture was stirred at 0 °C for 1 h before the dropwise 
addition of oct-7-yn-1-yl 4-methylbenzenesulfonate (1.40 g, 5.0 mmol) in anhydrous DMF 
(10 mL). Then reaction was allowed to warm to room temperature and stirred for 4 hours. 
The reaction mixture was quenched with NH4Cl (20 mL, sat. aq.) and the product was 
extracted with Et2O (50 mL × 3). The combined organic layer was washed with water (20 
mL), brine (20 mL), dried over MgSO4, and then concentrated under reduced pressure. The 
crude product was purified by silica column chromatography with hexane / ethyl acetate 
(10: 1) to afford 5h (1.10 g, 98%). 1H NMR (400 MHz, CDCl3) δ 3.96 (ddt, J = 11.5, 4.6, 
1.1 Hz, 2H), 3.43 – 3.34 (m, 4H), 3.24 (d, J = 6.6 Hz, 2H), 2.18 (td, J = 7.0, 2.7 Hz, 2H), 
1.93 (t, J = 2.7 Hz, 1H), 1.89 – 1.77 (m, 1H), 1.68 – 1.61 (m, 2H), 1.60 – 1.49 (m, 4H), 
1.46 – 1.34 (m, 4H), 1.33 – 1.25 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 84.80, 76.11, 
71.24, 68.28, 67.90, 35.60, 30.19, 29.70, 28.70, 28.56, 25.83, 18.49. HRMS (FAB) m/z: 
225.1855 (M + H+); calc. for C14H25O2: 225.1855. 
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((Oct-7-yn-1-yloxy)methyl)cyclopropane (5i) 
 
In a 100 mL round-bottom flask, cyclopropylmethanol 
(0.433 g, 6.0 mmol) and tetrabutylammonium bromide 
(161 mg, 0.5 mmol) were dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. 
NaH (60%, 240 mg, 6.0 mmol) was added portion-wise to the solution. The resulting 
mixture was stirred at 0 °C for 1 h before the dropwise addition of oct-7-yn-1-yl 4-
methylbenzenesulfonate (1.40 g, 5.0 mmol) in anhydrous DMF (10 mL). The reaction was 
allowed to warm to room temperature and stirred for 4 hours. The reaction mixture was 
quenched with NH4Cl (20 mL, sat. aq.) and the product was extracted with Et2O (50 mL × 
3). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over 
MgSO4, and then concentrated under reduced pressure. The crude product was purified by 
silica column chromatography with hexane / ether (50: 1) to afford 5i (840 mg, 93%). 1H 
NMR (400 MHz, CDCl3) δ 3.42 (t, J = 6.7 Hz, 2H), 3.24 (d, J = 6.9 Hz, 2H), 2.18 (td, J = 
7.0, 2.6 Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.64 – 1.57 (m, 2H), 1.56 – 1.49 (m, 2H), 1.47 – 
1.30 (m, 4H), 1.12 – 0.97 (m, 1H), 0.58 – 0.45 (m, 2H), 0.19 (dt, J = 6.0, 4.5 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 84.82, 75.73, 70.77, 68.26, 29.78, 28.72, 28.57, 25.85, 18.49, 
10.82, 3.13. HRMS (FAB) m/z: 181.1590 (M + H+); calc. for C12H21O: 181.1592. 
 
Trans-1-(methoxymethyl)-4-((oct-7-yn-1-yloxy)methyl)cyclohexane (5l) 
 
In a 100 mL round-bottom flask, (tran-
cyclohexane-1,4-diyl)dimethanol (2.88 g, 20.0 
mmol) and tetrabutylammonium bromide (32 
mg, 0.1 mmol) were dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH 
(60%, 960 mg, 24.0 mmol) was added portion-wise to the solution. The resulting mixture 
was stirred at 0 °C for 1 h before the dropwise addition of methyl iodide (MeI, 1.5 mL, 
24.0 mmol) in anhydrous DMF (10 mL). The reaction was allowed to warm to room 
temperature and stirred for 4 hours. The reaction mixture was quenched with NH4Cl (20 
mL, sat. aq.) and the product was extracted with Et2O (50 mL × 4). The combined organic 
layer was washed with water (50 mL), brine (50 mL), dried over MgSO4, and then 
concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane / ethyl acetate (1: 1) to afford (trans-4-
(methoxymethyl)cyclohexyl)methanol (2.02 g, 64%). 
In a 100 mL round-bottom flask, (trans-4-(methoxymethyl)cyclohexyl)methanol 
(0.949 g, 6.0 mmol) and tetrabutylammonium bromide (161 mg, 0.5 mmol) were dissolved 
in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) was 
added portion-wise to the solution. The resulting mixture was stirred at 0 °C for 1 h before 
the dropwise addition of oct-7-yn-1-yl 4-methylbenzenesulfonate (1.40 g, 5.0 mmol) in 
anhydrous DMF (10 mL). Then reaction was allowed to warm to room temperature and 
stirred for 4 hours. The reaction mixture was quenched with NH4Cl (20 mL, sat. aq.) and 
the product was extracted with Et2O (50 mL × 3). The combined organic layer was washed 
with water (20 mL), brine (20 mL), dried over MgSO4, and then concentrated under 
reduced pressure. The crude product was purified by silica column chromatography with 
hexane / ethyl acetate (10: 1) to afford 5l (743 mg, 56%). 1H NMR (400 MHz, CDCl3) δ 
3.38 (t, J = 6.6 Hz, 2H), 3.32 (s, 3H), 3.20 (d, J = 6.5 Hz, 2H), 3.18 (d, J = 6.4 Hz, 2H), 
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2.18 (td, J = 7.0, 2.7 Hz, 2H), 1.93 (t, J = 2.7 Hz, 1H), 1.86 – 1.74 (m, 4H), 1.58 – 1.49 (m, 
6H), 1.46 – 1.30 (m, 4H), 1.01 – 0.86 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 84.84, 78.93, 
76.90, 71.17, 68.26, 58.98, 38.37 (2 carbons), 29.73, 29.65, 29.55, 28.73, 28.58, 25.85, 
18.50. HRMS (FAB) m/z: 267.2325 (M + H+); calc. for C17H31O2: 267.2324. 
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VII. Synthesis of Racemic Cyclopropene Products  
 
Racemic cyclopropene products were prepared through rhodium-catalyzed 
cyclopropenation reactions, following the general procedure described below: 
 
General procedure for rhodium-catalyzed cyclopropenation: 
To a 20 mL vial was added alkyne (1.0 mmol, 1.0 equiv.), Rh2(OAc)4 (4.4 mg, 1 
mol%) and DCM (10 mL). The mixture was cooled to –78 °C, after which EDA (2.0 mmol, 
2.0 equiv.) was added dropwise to the solution. The reaction was allowed to slowly warm 
up to room temperature over 8 hours and stirred at room temperature for another 8 hours. 
Evaporation of the organic solvent and purification by silica column chromatography using 
hexane and ethyl acetate as eluents afforded racemic cyclopropene products 5a‒5i, 5k and 
5l in 10 ‒ 30% yields. (Note: this protocol did not work for cyclopropyl-substituted alkyne 
5j.) 
 
Racemic 6m was prepared through the following three-step synthetic sequence: 
To a 100 mL flask, hept-6-yn-1-ol (1.12 g, 10.0 mmol) and imidazole (885 mg, 13.0 
mmol) were dissolved in anhydrous DMF (50 mL). Tert-butylchlorodiphenylsilane 
(TBDPS‒Cl, 3.30 g, 12.0 mmol) was added to the solution. The resulting mixture was 
stirred for 6 hours. The reaction mixture was quenched with water (40 mL) and the product 
was extracted with Et2O (50 mL × 3). The combined organic layer was washed with water 
(20 mL), brine (20 mL), dried over MgSO4, and then concentrated under reduced pressure. 
The crude product was purified by silica column chromatography with hexane / ether (50: 
1) to afford tert-butyl(hept-6-yn-1-yloxy)diphenylsilane (3.44 g, 98%). 
To a 20 mL vial was added tert-butyl(hept-6-yn-1-yloxy)diphenylsilane (1.0 mmol, 
1.0 equiv.), Rh2(OAc)4 (4.4 mg, 1 mol%) and DCM (10 mL). The mixture was cooled to –
78 °C, after which EDA (2.0 mmol in 2 mL DCM, 2.0 equiv.) was added dropwise to the 
solution. The reaction was allowed to slowly warm up to room temperature in 8 hours and 
stirred at room temperature for another 8 hours. Evaporation of the organic solvent and 
purification by silica column chromatography with hexane / ethyl acetate (20: 1) as eluent 
afforded the crude cyclopropene product in ~30% yield. 
To a 10 mL flask, the protected cyclopropene product was dissolved in THF (8 mL). 
Tetrabutylammonium fluoride (TBAF, 1M in THF, 0.9 mL) was added to the solution. The 
resulting mixture was stirred at room temperature for 5 h. Evaporation of the organic 
solvent and purification by silica column chromatography with hexane / ethyl acetate (1.5: 
1) as eluent afforded the racemic cyclopropene 6m (48 mg, ~80% yield). 
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VIII. Enzymatic Bicyclobutane Formation at Analytical and Preparative Scale 
 
All enzymatic reactions for bicyclobutane formation at analytical scale were 
conducted following the general procedure described below and analyzed with gas 
chromatography (GC). All TTNs for the different products were approximated using the 
GC standard curve of bicyclobutane 2a, assuming substituents on the phenyl ring will not 
significantly affect the GC signals. These estimated TTNs were only used to help determine 
the reaction scale required to obtain sufficient bicyclobutane products for isolation, 
purification and characterization.  
 
General procedure for analytical-scale reactions:  
To a 2 mL vial were added degassed suspension of E. coli expressing P411-E10 V78F 
S438A variant in M9-N buffer (OD600 = 9, 340 μL), alkyne (10 μL of 200 mM stock 
solution in EtOH, 5 mM final concentration), EDA (10 μL of 400 mM stock solution in 
EtOH, 10 mM final concentration, 2.0 equiv.), D-glucose (40 μL of 250 mM stock solution 
in M9-N buffer, 25 mM final concentration) under anaerobic conditions. The vial was 
capped and shaken at 560 rpm at room temperature for 6 h. After the reaction was 
completed, internal standard 1,3,5-trimethoxybenzene (20 μL of 20 mM stock solution in 
toluene) was added to the reaction vial followed by mixed solvent (cyclohexane / ethyl 
acetate = 1 : 1, 1 mL). The mixture was transferred to a 1.5 mL microcentrifuge tube, and 
then vortexed (15 s × 3) and centrifuged (14,000 rpm, 5 min) to completely separate the 
organic and aqueous layers. 0.8 mL of organic layer was taken for GC analysis. TTN was 
calculated based on measured protein concentration. Reactions for every substrate were set 
up in quadruplicate. 
 
GC standard curve of bicyclobutane 2a: 
All data points represent the average of duplicate runs. The standard curves plot 
product concentration in mM (y-axis) against the ratio of product area to internal standard 
area on the GC (x-axis). 
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Result of analytic reactions: 
 
Figure S15. Result of analytic reactions for bicyclobutane formation 
 
Table S9. Analysis data of analytical reactions 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
2a-(1) 3012.4 593.0 5.080 3.12 1.66 1882   
2a-(2) 3010.1 580.6 5.184 3.18 1.66 1921   
2a-(3) 2851.0 585.8 4.867 2.98 1.66 1803   
2a-(4) 2921.9 565.9 5.163 3.17 1.66 1913 1880 62.2 
2b-(1) 3204.9 554.0 5.785 3.47 1.66 2097   
2b-(2) 3278.8 558.0 5.876 3.53 1.66 2130   
2b-(3) 3274.2 565.1 5.794 3.48 1.66 2100   
2b-(4) 3154.2 559.6 5.637 3.38 1.66 2043 2092 69.3 
2c-(1) 2479.6 549.9 4.509 2.71 1.66 1634   
2c-(2) 2406.8 577.9 4.165 2.50 1.66 1510   
2c-(3) 2317.3 577.5 4.013 2.41 1.66 1455   
2c-(4) 2185.1 587.0 3.722 2.23 1.66 1349 1438 49.2 
2d-(1) 2007.2 576.5 3.482 2.09 1.66 1262   
2d-(2) 1673.5 564.7 2.964 1.78 1.66 1074   
2d-(3) 1436.5 570.1 2.520 1.51 1.66 913   
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2d-(4) 1572.0 559.6 2.809 1.69 1.66 1018 1067 35.3 
2e-(1) 2712.6 551.2 4.921 2.95 1.66 1784   
2e-(2) 2943.0 575.5 5.114 3.07 1.66 1854   
2e-(3) 2565.4 556.1 4.613 2.77 1.66 1672   
2e-(4) 2725.3 558.7 4.878 2.93 1.66 1768 1769 58.6 
2f-(1) 1265.4 582.8 2.171 1.30 1.66 787   
2f-(2) 1261.3 583.0 2.163 1.30 1.66 784   
2f-(3) 1247.4 574.0 2.173 1.30 1.66 788   
2f-(4) 1194.4 580.7 2.057 1.23 1.66 746 773 25.7 
2g-(1) 2899.6 605.2 4.791 2.87 1.66 1737   
2g-(2) 2881.5 587.1 4.908 2.94 1.66 1779   
2g-(3) 2797.3 586.1 4.773 2.86 1.66 1730   
2g-(4) 2657.8 571.2 4.653 2.79 1.66 1687 1733 57.4 
2j-(1) 244.5 605.1 0.404 0.24 1.66 147   
2j-(2) 255.0 625.4 0.408 0.24 1.66 148   
2j-(3) 256.9 618.4 0.415 0.25 1.66 151   
2j-(4) 231.0 633.1 0.365 0.22 1.66 132 145 4.8 
2k-(1) 2837.1 565.1 5.021 3.01 1.66 1820   
2k-(2) 2818.8 591.5 4.766 2.86 1.66 1727   
2k-(3) 2792.4 572.9 4.874 2.92 1.66 1767   
2k-(4) 2824.5 581.3 4.859 2.92 1.66 1761 1769 58.6 
2l-(1) 1921.1 566.3 3.392 2.04 1.66 1230   
2l-(2) 1703.9 549.4 3.101 1.86 1.66 1124   
2l-(3) 1797.8 565.5 3.179 1.91 1.66 1152   
2l-(4) 1656.7 565.1 2.932 1.76 1.66 1063 1113 37.8 
 
Note: Pdt = product area on GC, Std = internal standard area on GC, [Pdt] = product 
concentration in reaction mixture, [PC] = protein concentration in initial reaction mixture, 
Avg. = average. 
 
All enzymatic reactions for bicyclobutane formation at preparative scale were 
conducted following the general procedure described below and the corresponding 
bicyclobutane products were isolated. Detailed conditions for the preparative-scale 
reactions of different substrates are indicated separately. 
 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing 
P411 E10-V78F S438A variant (OD600 = 10 ‒ 20), alkyne (0.1 ‒ 0.2 mmol, larger scales 
for 1k‒1m), EDA (2.0 ‒ 4.0 equiv.), D-glucose (10 – 15 mM, 250 mM stock in M9-N), 1 
– 5 vol% EtOH, M9-N buffer (pH 7.4) under anaerobic conditions. The vial or flask was 
capped and shaken (420 rpm for vials and 220 rpm for flasks) at room temperature for 12 
h. 
After the reaction was completed, every 30 mL portion of preparative-scale reaction 
mixture was transferred to a 50 mL Falcon centrifuge tube. The reaction container was 
washed with water (2 mL × 2) followed by mixed organic solvent (cyclohexane / ethyl 
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acetate = 1 : 1, 2 mL × 3). The washing solution was combined with the reaction mixture 
in the centrifuge tubes. Additional 12 mL of cyclohexane / ethyl acetate solvent was added 
to every tube. After the tube (with ~45 mL mixture in total) was capped, it was vortexed 
(1 min × 3), shaken vigorously, and centrifuged (14,000 g, 5 min). The organic layer was 
separated and the aqueous layer was subjected to three more rounds of extraction. Then 
organic layers were combined, dried over Na2SO4, and concentrated under reduced 
pressure. Purification by silica column chromatography with hexane / ethyl acetate as 
eluent afforded the desired bicyclobutanes. TTNs were calculated based on measured 
protein concentration and the isolated yield of the product. 
 
Diethyl (2R,4R)-1-phenylbicyclo[1.1.0]butane-2,4-dicarboxylate (2a) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 24.0 4.17 0.100 1.0 ~10 
alkyne (1a) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.00 180 0.18 2.00 180 0.36 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
31.3 0.114 63% 1140 
 
Note: [PC] = protein concentration in original cell suspension, n_pro = amount of protein 
in the reaction, [Glu] = D-glucose concentration in reaction mixture, n_1 = amount of 
alkyne in the reaction, n_2 = amount of EDA in the reaction, m[Pdt] = mass of product 
isolated, n[Pdt] = amount of product. The same for the following tables. 
 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.22 (m, 5H), 4.14 (qd, J = 7.2, 
2.4 Hz, 2H), 4.07 (qd, J = 7.2, 3.7 Hz, 2H), 3.26 (s, 1H), 3.13 (d, J = 
3.0 Hz, 1H), 3.10 (d, J = 3.0 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.36, 167.91, 
132.68, 128.50, 128.45, 127.56, 60.99, 60.91, 44.64, 42.55, 28.18, 
20.47, 14.37, 14.16. HRMS (FAB) m/z: 275.1271 (M + H+); calc. 
for C16H19O4: 275.1283. [α]23D = ‒124.8 ± 1.1° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-fluorophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2b) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 24.0 4.17 0.100 1.0 ~10 
alkyne (1b) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 180 0.18 2.0 180 0.36 
purification eluent product 
Ethyl acetate in hexanes m[Pdt]/mg n[Pdt]/mmol yield TTN 
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(0% to 10% gradient) 36.6 0.125 70% 1250 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.26 (m, 2H), 7.05 – 6.94 (m, 
2H), 4.21 – 4.11 (m, 2H), 4.11 – 4.00 (m, 2H), 3.23 (d, J = 0.5 Hz, 
1H), 3.09 (d, J = 3.0 Hz, 1H), 3.04 (dd, J = 3.0, 0.6 Hz, 1H), 1.27 
(t, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.20, 167.80, 163.59 (d, JC-F = 246.4 Hz), 130.55 (d, 
JC-F = 8.2 Hz), 128.31, (d, JC-F = 3.3 Hz), 115.63, (d, JC-F = 21.8 
Hz), 61.06, 60.98, 44.83, 42.70, 27.50, 19.89, 14.37, 14.20. HRMS 
(FAB) m/z: 293.1179 (M + H+); calc. for C16H18FO4: 293.1189. 
[α]23D = ‒110.1 ± 2.0° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-chlorophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2c) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 36.0 4.17 0.150 1.5 ~10 
alkyne (1c) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 200 0.20 2.0 400 0.80 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
45.2 0.146 73% 980 
 
1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.9 Hz, 2H), 7.23 (d, J = 
8.6 Hz, 2H), 4.14 (qd, J = 7.1, 2.4 Hz, 2H), 4.08 (qd, J = 7.1, 2.2 Hz, 
2H), 3.24 (d, J = 0.6 Hz, 1H), 3.10 (d, J = 3.0 Hz, 1H), 3.08 (dd, J = 
3.0, 0.5 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.06, 167.75, 133.48, 131.27, 
129.93, 128.71, 61.10, 61.06, 44.77, 42.65, 27.47, 20.61, 14.36, 
14.21. HRMS (FAB) m/z: 309.0902 (M + H+); calc. for C16H18ClO4: 
309.0894. [α]23D = ‒141.5 ± 2.6° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-bromophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2d) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 36.0 4.17 0.150 1.5 ~10 
alkyne (1d) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 300 0.60 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
42.5 0.120 80% 800 
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1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 
8.7 Hz, 2H), 4.14 (qd, J = 7.1, 2.4 Hz, 2H), 4.08 (qd, J = 7.1, 1.8 Hz, 
2H), 3.24 (d, J = 0.6 Hz, 1H), 3.10 (d, J = 3.1 Hz, 1H), 3.09 (dd, J = 
3.1, 0.5 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 170.02, 167.73, 131.84, 131.64, 130.22, 
121.56, 61.11, 61.07, 44.74, 42.62, 27.53, 20.71, 14.36, 14.21. HRMS 
(FAB) m/z: 353.0399 (M + H+); calc. for C16H18BrO4: 353.0388 
(79Br). [α]23D = ‒128.4 ± 0.8° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(p-tolyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2e) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 20.0 2.92 0.0584 1.0 ~13 
alkyne (1e) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
29.6 0.103 64% 1760 
 
1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 
7.9 Hz, 2H), 4.18 – 4.03 (m, 4H), 3.23 (d, J = 0.6 Hz, 1H), 3.08 (dd, 
J = 3.0, 0.6 Hz, 1H), 3.06 (d, J = 3.0 Hz, 1H), 2.32 (s, 3H), 1.26 (t, 
J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.48, 168.01, 137.37, 129.42, 129.22, 128.41, 60.94, 
60.87, 44.62, 42.50, 28.09, 21.34, 20.07, 14.37, 14.20. HRMS 
(FAB) m/z: 289.1450 (M + H+); calc. for C17H21O4: 289.1440. [α]23D 
= ‒143.6 ± 1.0° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-ethylphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2f) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 32.0 2.92 0.0934 1.5 ~11 
alkyne (1f) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 100 0.10 2.0 100 0.20 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
16.8 0.0556 56% 600 
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1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 
8.4 Hz, 2H), 4.20 – 4.01 (m, 4H), 3.23 (d, J = 0.6 Hz, 1H), 3.09 (dd, 
J = 3.0, 0.6 Hz, 1H), 3.07 (d, J = 3.0 Hz, 1H), 2.62 (q, J = 7.6 Hz, 
2H), 1.26 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 7.6 Hz, 3H), 1.14 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.49, 168.02, 143.73, 
129.69, 128.46, 128.04, 60.93, 60.87, 44.57, 42.50, 28.72, 28.13, 
20.14, 15.67, 14.38, 14.19. HRMS (FAB) m/z: 303.1588 (M + H+); calc. for C18H23O4: 
303.1596. [α]23D = ‒133.7 ± 1.8° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(3-methoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2g) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 20.0 2.92 0.0584 1.0 ~13 
alkyne (1g) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
27.2 0.0894 56% 1530 
 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.88 (ddd, J = 
7.6, 1.6, 1.0 Hz, 1H), 6.85 – 6.82 (m, 1H), 6.80 (ddd, J = 8.2, 2.6, 
1.0 Hz, 1H), 4.20 – 4.01 (m, 4H), 3.78 (s, 3H), 3.25 (d, J = 0.6 Hz, 
1H), 3.13 (dd, J = 3.0, 0.6 Hz, 1H), 3.09 (d, J = 3.0 Hz, 1H), 1.26 
(t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.31, 167.90, 159.67, 134.22, 129.54, 120.75, 114.01, 
113.20, 61.01, 60.95, 55.35, 44.69, 42.58, 28.18, 20.69, 14.37, 14.20. HRMS (FAB) m/z: 
305.1383 (M + H+); calc. for C17H21O5: 305.1389. [α]23D = ‒122.6 ± 1.5° (c 0.1, ethyl 
acetate). 
 
Diethyl (2R,4R)-1-(3,5-dimethoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2h) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 45.0 2.54 0.114 3.0 ~16 
alkyne (1h) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 225 0.45 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
19.8 0.0592 40% 520 
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1H NMR (400 MHz, CDCl3) δ 6.44 (d, J = 2.2 Hz, 2H), 6.36 (t, J = 
2.3 Hz, 1H), 4.15 (qd, J = 7.1, 2.5 Hz, 2H), 4.09 (qd, J = 7.1, 3.9 
Hz, 2H),3.76 (s, 6H), 3.24 (s, 1H), 3.12 (d, J = 3.0 Hz, 1H), 3.09 (d, 
J = 3.0 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.14, 167.76, 160.71, 134.80, 
106.29, 99.71, 60.88, 60.84, 55.33, 44.56, 42.45, 28.23, 20.67, 
14.23, 14.11. HRMS (FAB) m/z: 335.1480 (M + H+); calc. for C18H23O6: 335.1495. [α]23D 
= ‒144.6 ± 3.5° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(3-hydroxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2i) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 45.0 2.14 0.0963 3.0 ~16 
alkyne (1i) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 120 0.12 2.0 180 0.36 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 20% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
10.4 0.0358 30% 370 
 
1H NMR (400 MHz, CDCl3) δ 7.15 (td, J = 8.1, 1.7 Hz, 1H), 6.87 – 
6.83 (m, 1H), 6.78 – 6.74 (m, 1H), 6.73 – 6.68 (m, 1H), 5.06 (s, 1H), 
4.21 – 4.02 (m, 4H), 3.23 (d, J = 0.6 Hz, 1H), 3.11 (dd, J = 3.1, 0.6 
Hz, 1H), 3.09 (d, J = 3.0 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.15 (t, J 
= 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.22, 167.87, 
155.59, 134.27, 129.62, 120.76, 115.15, 114.58, 60.94, 60.92, 44.54, 
42.43, 27.86, 20.58, 14.23, 14.04. HRMS (FAB) m/z: 291.1237 (M + H+); calc. for 
C16H19O5: 291.1232. 
 
Diethyl (2R,4R)-1-(thiophen-2-yl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2j) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 54.0 4.30 0.232 3.2 ~14 
alkyne (1j) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 100 0.10 2.0 200 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
11.4 0.0407 41% 160 
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1H NMR (400 MHz, CDCl3) δ 7.20 (dd, J = 5.2, 1.2 Hz, 1H), 7.05 
(dd, J = 3.5, 1.3 Hz, 1H), 6.94 (dd, J = 5.2, 3.5 Hz, 1H), 4.19 – 4.10 
(m, 4H), 3.27 (s, 1H), 3.10 (d, J = 3.1 Hz, 1H), 3.06 (dd, J = 3.1, 0.6 
Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.92, 167.46, 135.29, 128.55, 126.97, 
125.42, 61.14, 61.12, 45.87, 44.10, 23.88, 21.23, 14.37, 14.22. 
HRMS (FAB) m/z: 281.0839 (M + H+); calc. for C14H17O4S: 281.0848. 
 
Diethyl (2R,4R)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2k) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
15 24.0 2.43 0.0583 1.0 ~10 
alkyne (1k) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
32.4 0.107 67% 1830 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 600 2.96 1.77 30 ~12 
alkyne (1k) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/mM volume/mL n_2/mmol 
2.0 2.40 4.80 2.0 7.20 14.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
680.4 2.34 47% 1260 
 
Note: in 4.8 mmol scale reaction, the EDA stock solution was added in three portions (2.4 
mL each portion) every 1 hour. 
 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 
8.7 Hz, 2H), 4.20 – 3.99 (m, 4H), 3.79 (s, 3H), 3.21 (s, 1H), 3.04 (d, 
J = 2.9 Hz, 1H), 3.01 (d, J = 2.9 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 
1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.53, 
168.01, 159.21, 130.03, 124.27, 113.99, 60.93, 60.85, 55.43, 44.68, 
42.63, 27.90, 19.35, 14.38, 14.22. HRMS (FAB) m/z: 305.1375 (M 
+ H+); calc. for C17H21O5: 305.1389. [α]23D = ‒138.2 ± 1.6° (c 0.1, 
ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-ethynylxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2l) 
 
E. coli suspension in M9-N D-glucose in M9-N 
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OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 36.0 3.44 0.124 2.0 ~13 
alkyne (1l) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 225 0.45 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
28.7 0.0962 64% 780 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 600 3.03 1.82 30 ~12 
alkyne (1l) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 1.40 2.80 2.0 4.20 8.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
393.7 1.32 47% 730 
 
Note: in 2.8 mmol scale-reaction, EDA stock solution was added in three portions (1.4 mL 
each portion) every 1 hour. 
 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 
8.6 Hz, 2H), 4.17 (qd, J = 7.2, 2.9 Hz, 2H), 4.11 (qd, J = 7.1, 0.6 Hz, 
2H), 3.29 (d, J = 0.6 Hz, 1H), 3.18 (dd, J = 3.1, 0.6 Hz, 1H), 3.15 (d, 
J = 3.1 Hz, 1H), 3.11 (s, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.17 (t, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.04, 167.73, 133.79, 
132.24, 128.28, 121.22, 83.47, 77.86, 61.12, 61.07, 44.73, 42.67, 
27.88, 21.40, 14.36, 14.19. HRMS (FAB) m/z: 299.1282 (M + H+); 
calc. for C18H19O4: 299.1283. [α]23D = ‒152.6 ± 3.1° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-(hydroxymethyl)phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate 
(2m) 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 75.0 3.72 0.279 4.0 ~13 
alkyne (1m) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 2.0 540 1.08 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
52.8 0.174 48% 630 
 
  
38 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 160 2.68 0.428 10 ~15 
alkyne (1m) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 1.00 1.00 2.0 2.00 4.00 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
152.1 0.500 50% 580 
 
Note: in a 1.0 mmol-scale reaction, EDA stock solution was added in four portions (0.5 
mL each portion) every 1 hour. 
 
1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 2.5 Hz, 4H), 4.68 (d, J = 
5.0 Hz, 2H), 4.14 (qd, J = 7.1, 2.3 Hz, 2H), 4.08 (qd, J = 7.1, 0.9 Hz, 
2H), 3.26 (d, J = 0.5 Hz, 1H), 3.13 (dd, J = 3.1, 0.6 Hz, 1H), 3.10 (d, 
J = 3.0 Hz, 1H), 1.62 (t, J = 5.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 
1.16 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.30, 
167.93, 140.24, 132.11, 128.68, 127.15, 65.20, 61.02, 60.96, 44.72, 
42.54, 27.96, 20.58, 14.37, 14.22. HRMS (FAB) m/z: 303.1230 ((M 
+ H+) ‒ H2); calc. for C17H19O5: 303.1232. [α]23D = ‒130.8 ± 1.2° (c 0.1, ethyl acetate). 
 
 
Notes: 
1. During testing of analytical reactions, electron-withdrawing alkynes 1n and 1o also gave 
fair amount of products, which was detected by GC-MS. But we had problems in isolating 
these products from preparative-scale reactions. These results are noteworthy, but they 
cannot be used for drawing conclusions before further validation. 
2. The enantioselectivities of bicyclobutane products are difficult to determine, as there is 
no method in the literature to prepare the racemic standards. We attempted to determine 
the enantiopurities of the bicyclobutane products by chiral HPLC. Purified bicyclobutanes 
2a‒2c, 2e, 2k and 2l (with >98% purity by 1H NMR) were tested under various analytical 
chiral HPLC separation conditions using with Chirlapak IA, IC, AS-H, and OJ-H columns. 
In all cases, only one major peak was detected for each product (with >98% peak area at 
254 nm). In order to determine whether any of the minor peaks (with 0.5‒1% peak area at 
254 nm) detected corresponds to an enantiomer of the desired product, we collected and 
concentrated those fractions for further UV testing (210‒280 nm) and GC-MS testing; none 
turned out to be the enantiomers of the bicyclobutanes. It is thus likely that the 
bicyclobutanes have high enantiopurity, though we cannot fully rule out the possibility that 
the enantiomers might not be resolved under any of the chiral HPLC condition tested. 
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IX. Enzymatic Cyclopropene Formation at Analytical and Preparative Scale 
 
All enzymatic reactions for cyclopropene formation at analytical scale were 
conducted following the general procedure described below and analyzed with gas 
chromatography (GC). All TTNs for the different products were determined using the GC 
standard curve of the corresponding racemic standard product made with Rh2(OAc)4 (see 
Section VII). These TTNs were used to guide set-up of preparative-scale reactions.  
 
General procedure for analytical-scale reactions:  
To a 2 mL vial were added degassed suspension of E. coli expressing P411-C6 or 
K10 variant in M9-N buffer (OD600 = 15, 340 μL), alkyne (10 μL of 400 or 800 mM stock 
solution in EtOH, 10 or 20 mM), EDA (10 μL of 400 or 800 mM stock solution in EtOH, 
10 or 20 mM, 1.0 equiv.), D-glucose (40 μL of 250 mM stock solution in M9-N buffer, 25 
mM) under anaerobic conditions. The vial was capped and shaken at 560 rpm at room 
temperature for 6 h. After the reaction was completed, internal standard 1,3,5-
trimethoxybenzene (20 μL of 20 mM stock solution in toluene) was added to the reaction 
vial followed by mixed solvent (cyclohexane / ethyl acetate = 1 : 1, 1 mL). The mixture 
was transferred to a 1.5 mL microcentrifuge tube, and then vortexed (15 seconds × 3) and 
centrifuged (14,000 rpm, 5 min) to completely separate the organic and aqueous layers. 0.8 
mL of organic layer was taken for GC analysis. TTN was calculated based on measured 
protein concentration. Enantioselectivity was measured by chiral HPLC. Reactions for 
every substrate were set up in triplicate or quadruplicate. 
 
GC standard curve: 
All data points represent the average of duplicate runs. The standard curves plot 
product concentration in mM (y-axis) against the ratio of product area to internal standard 
area on the GC (x-axis). 
 
All enzymatic reactions for cyclopropene formation at preparative scale were 
conducted following the general procedure described below and the corresponding 
cyclopropene products were isolated. Detailed conditions for preparative-scale reactions of 
different substrates are indicated separately. 
 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing 
P411-C6 or K10 variant (OD600 = 10 ‒ 60), alkyne (0.08 ‒ 0.4 mmol, larger scales for 5a 
and 5h), EDA (1.0 ‒ 4.0 equiv.), D-glucose (10 – 15 mM, 250 mM stock in M9-N), 1 – 5 
vol% EtOH, M9-N buffer (pH 7.4) under anaerobic conditions. The vial or flask was 
capped and shaken (420 rpm for vials and 220 rpm for flasks) at room temperature for 12 
h. 
After the reaction was completed, every 30 mL portion of preparative-scale reaction 
mixture was transferred to a 50 mL Falcon centrifuge tube. The reaction container was 
washed with water (2 mL × 2) followed by mixed organic solvent (cyclohexane / ethyl 
acetate = 1 : 1, 2 mL × 3). The washing solution was combined to reaction mixture in 
centrifuge tubes. An additional 12 mL of cyclohexane / ethyl acetate solvent was added to 
every tube. After the tube (with ~45 mL mixture in total) was capped, it was vortex (1 min 
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× 3) and shaken vigorously, and centrifuged (14,000 g, 5 min). The organic layer was 
separated and the aqueous layer was subjected to three more rounds of extraction. The 
organic layers were combined, dried over Na2SO4 and concentrated under reduced 
pressure. Purification by silica column chromatography with hexane / ethyl acetate as 
eluent afforded the desired cyclopropenes. Enantioselectivity was measured by chiral 
HPLC. TTNs were calculated based on measured protein concentration and isolated 
product yield. 
 
Ethyl (S)-2-phenethylcycloprop-2-ene-1-carboxylate (S-6a) 
GC calibration curve:  
 
 
Analysis data (10 mM 5a, P411-K10): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6a-(1) 4637.1 590.6 7.852 6.24 1.93 3242   
6a-(2) 4639.5 592.1 7.836 6.23 1.93 3236   
6a-(3) 4797.4 582.9 8.230 6.54 1.93 3399   
6a-(4) 4674.5 588.0 7.950 6.32 1.93 3283 3290 63.3% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-K10 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 28.0 3.12 0.0874 1.5 ~13 
alkyne (5a) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
37.8 0.175 44% 2000 
 
y = 0.795x
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0
2
4
6
8
10
12
0 2 4 6 8 10 12 14
C
o
n
ce
n
tr
at
io
n
 /
 m
M
Product / Standard
Ph-C4-ene Product
  
41 
 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.24 – 7.18 (m, 
3H), 6.36 (dt, J = 1.4 Hz, 1H), 4.21 – 4.05 (m, 2H), 2.96 – 2.79 (m, 
4H), 2.14 (d, J = 1.5 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 176.61, 140.81, 128.58, 128.45, 126.36, 115.01, 
95.03, 60.39, 33.00, 26.90, 20.00, 14.52. HRMS (FAB) m/z: 217.1221 (M + H+); calc. for 
C14H17O2: 217.1229. [α]23D = ‒ 64.7 ± 3.6° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 8.89 min (minor), 9.20 min 
(major), 99.55:0.45 er. 
 
Ethyl (R)-2-phenethylcycloprop-2-ene-1-carboxylate (R-6a) 
 
Analysis data (10 mM 5a, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6a-(1) 4577.9 511.2 8.955 7.12 2.83 2518   
6a-(2) 4659.1 515.1 9.045 7.19 2.83 2543   
6a-(3) 4647.7 518.4 8.965 7.13 2.83 2521   
6a-(4) 4608.7 518.6 8.887 7.07 2.83 2499 2520 71.3% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 28.0 4.04 0.113 1.5 ~13 
alkyne (5a) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
46.8 0.216 54% 1910 
 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
24 800 5.35 4.28 50 ~15 
alkyne (5a) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 2.50 5.0 2.0 7.50 15.0 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
824.1 3.81 76% 1780 
Note: in 5.0-mmol scale reaction, EDA stock solution was added in three portions (2.5 mL 
each portion) every 1 hour. 
 
[α]23D = + 62.2 ± 2.5° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 9.05 min 
(major), 9.42 min (minor), 99.95:0.05 er. 
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Ethyl (R)-2-octylcycloprop-2-ene-1-carboxylate (6b) 
GC calibration curve:  
 
 
Analysis data (10 mM 5b, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6b-(1) 1195.2 523.7 2.282 1.49 1.82 815   
6b-(2) 1128.3 528.7 2.134 1.39 1.82 763   
6b-(3) 1023.1 521.4 1.962 1.28 1.82 701 760 13.9% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 60.0 3.83 0.230 1.5 ~12 
alkyne (5b) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 250 0.20 0.80 250 0.20 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
27.2 0.121 61% 530 
Note: cell suspension (OD600 = 20) was added in three portions (20 mL each portion) every 
2 hours. 
 
1H NMR (400 MHz, CDCl3) δ 6.31 (dt, J = 1.4 Hz, 1H), 4.12 (qd, J = 
7.1, 5.0 Hz, 2H), 2.48 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 
1H), 1.61 – 1.52 (m, 2H), 1.35 – 1.22 (m, 13H), 0.91 – 0.83 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.80, 115.77, 94.01, 60.28, 31.97, 
29.39, 29.32, 29.27, 26.80, 25.10, 22.79, 19.86, 14.52, 14.24. HRMS (FAB) m/z: 225.1862 
(M + H+); calc. for C14H25O2: 225.1855. [α]23D = + 32.6 ± 1.8° (c 0.1, cyclohexane) [Note: 
(S)-5b (87% ee) was reported with [α]23D = ‒ 30° (c 1.55, CHCl3) (16)]. HPLC Chiralpak 
y = 0.6519x
R² = 0.9998
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IC column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 6.59 min (major), 7.10 min 
(minor), 98.0:2.0 er. 
 
Ethyl (R)-2-(hex-5-yn-1-yl)cycloprop-2-ene-1-carboxylate (6c) 
GC calibration curve:  
 
 
Analysis data (20 mM 5c, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6c-(1) 1084.2 344.6 3.146 2.39 1.67 1434   
6c-(2) 1164.4 407.1 2.860 2.17 1.67 1304   
6c-(3) 1079.9 385.7 2.800 2.13 1.67 1276   
6c-(4) 985.5 350.1 2.815 2.14 1.67 1283 1324 11.1% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 30.0 6.33 0.190 1.5 ~12 
alkyne (5c) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 6% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
46.2 0.240 60% 1260 
 
1H NMR (400 MHz, CDCl3) δ 6.35 (dt, J = 1.5 Hz, 1H), 4.20 – 4.04 
(m, 2H), 2.52 (td, J = 7.2, 1.4 Hz, 2H), 2.21 (td, J = 6.9, 2.6 Hz, 2H), 
2.13 (d, J = 1.6 Hz, 1H), 1.94 (t, J = 2.6 Hz, 1H), 1.71 (dtd, J = 8.7, 
7.1, 5.4 Hz, 2H), 1.60 (dtd, J = 9.1, 6.9, 4.9 Hz, 2H), 1.24 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.63, 115.25, 94.60, 84.14, 68.69, 60.33, 27.89, 
25.84, 24.63, 19.85, 18.23, 14.51. HRMS (FAB) m/z: 193.1220 (M + H+); calc. for 
y = 0.7598x
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C12H17O2: 193.1229. [α]23D = + 52.2 ± 1.8° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 10.37 min (major), 11.55 min 
(minor), 98.0:2.0 er. 
 
(R)-6-(3-(Ethoxycarbonyl)cycloprop-1-en-1-yl)hexyl cyclobutanecarboxylate (6d) 
GC calibration curve:  
 
 
Analysis data (10 mM 5d, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6d-(1) 24642 4192 5.878 3.88 2.01 1930   
6d-(2) 22575 4190 5.388 3.56 2.01 1769   
6d-(3) 22572 4242 5.321 3.51 2.01 1747   
6d-(4) 24260 4249 5.710 3.77 2.01 1875 1831 36.8% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
32 25.0 6.48 0.162 1.5 ~11 
alkyne (5d) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 1.0 900 0.90 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
56.7 0.193 54% 1190 
 
1H NMR (400 MHz, CDCl3) δ 6.33 (dt, J = 1.5 Hz, 1H), 4.17 – 
4.08 (m, 2H), 4.05 (t, J = 6.7 Hz, 2H), 3.12 (p, J = 8.5 Hz, 1H), 
2.49 (td, J = 7.3, 1.1 Hz, 2H), 2.33 – 2.13 (m, 4H), 2.12 (d, J = 
1.6 Hz, 1H), 2.05 – 1.82 (m, 2H), 1.66 – 1.55 (m, 4H), 1.43 – 
1.32 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.74, 175.74, 
y = 0.6601x
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115.55, 94.26, 64.38, 60.33, 38.29, 28.87, 28.68, 26.68, 25.74, 25.42, 25.03, 19.85, 18.56, 
14.54. HRMS (FAB) m/z: 295.1910 (M + H+); calc. for C17H27O4: 295.1909. [α]23D = + 
31.7 ± 1.7° (c 0.1, cyclohexane). HPLC Chiralpak IC column (n-hexane/isopropanol = 
91:9, 1.0 mL/min), tr = 17.06 min (major), 19.06 min (minor), 95.3:4.7 er. 
 
Ethyl (R)-2-(5-(1,3-dioxolan-2-yl)pentyl)cycloprop-2-ene-1-carboxylate (6e) 
GC calibration curve:  
 
 
Analysis data (10 mM 5e, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6e-(1) 7788 4377 1.779 1.48 1.77 838   
6e-(2) 7579 4283 1.770 1.47 1.77 834   
6e-(3) 7654 4377 1.749 1.46 1.77 824   
6e-(4) 7263 4296 1.691 1.41 1.77 797 823 14.6% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
24 50.0 5.32 0.266 2.0 ~10 
alkyne (5e) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 240 0.24 1.0 720 0.72 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
42.8 0.168 70% 630 
Note: cell suspension (OD600 = 24) was added in two portions (25 mL each portion) every 
2 hours. 
 
y = 0.8331x
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1H NMR (400 MHz, Acetone-d6) δ 6.61 (dt, J = 1.5 Hz, 1H), 4.81 
(t, J = 4.8 Hz, 1H), 4.09 (qd, J = 7.1, 2.3 Hz, 2H), 3.98 – 3.88 (m, 
2H), 3.87 – 3.76 (m, 2H), 2.54 (tdd, J = 7.1, 2.2, 1.4 Hz, 2H), 2.07 
(d, J = 1.6 Hz, 1H), 1.67 – 1.57 (m, 4H), 1.52 – 1.41 (m, 4H), 1.23 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Acetone-d6) δ 175.78, 115.81, 104.67, 94.74, 
65.05, 59.93, 34.29, 27.09, 25.03, 24.19, 19.69, 14.44 (one carbon peak may be 
overlapping with the solvent peaks). HRMS (FAB) m/z: 255.1593 (M + H+); calc. for 
C14H23O4: 255.1596. [α]23D = + 29.8 ± 1.3° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 15.03 min (major), 16.92 min 
(minor), 96.8:3.2 er. 
 
Ethyl (R)-2-(3-isopropoxypropyl)cycloprop-2-ene-1-carboxylate (6f) 
GC calibration curve:  
 
 
Analysis data (10 mM 5f, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6f-(1) 212.9 504.7 0.422 0.38 1.82 207   
6f-(2) 289.9 514.0 0.564 0.50 1.82 276   
6f-(3) 252.4 511.2 0.494 0.44 1.82 242 242 4.4% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.27 0.251 2.0 ~12 
alkyne (5f) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
800 100 0.08 800 300 0.24 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
13.6 0.0641 80% 260 
y = 0.8938x
R² = 0.9998
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1H NMR (400 MHz, CDCl3) δ 6.34 (dt, J = 1.4 Hz, 1H), 4.12 (qd, J = 
7.1, 4.2 Hz, 2H), 3.53 (hept, J = 6.2 Hz, 1H), 3.45 (td, J = 6.3, 1.9 Hz, 
2H), 2.58 (td, J = 7.3, 1.4 Hz, 2H), 2.13 (d, J = 1.5 Hz, 1H), 1.88 – 
1.78 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.13 (d, J = 6.1 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 176.69, 115.36, 94.47, 71.61, 66.92, 60.31, 27.43, 22.24, 22.02, 
19.89, 14.51. HRMS (FAB) m/z: 213.1485 (M + H+); calc. for C12H21O3: 213.1491. HPLC 
Chiralpak IC column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 9.42 min (major), 
10.92 min (minor), 97.3:2.7 er. 
 
Ethyl (R)-2-(cyclohexylmethyl)cycloprop-2-ene-1-carboxylate (6g) 
GC calibration curve:  
 
 
Analysis data (20 mM 5g, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6g-(1) 1044.5 704.1 1.483 0.97 1.67 585   
6g-(2) 903.7 654.8 1.380 0.91 1.67 544   
6g-(3) 1102.7 701.6 1.572 1.03 1.67 620   
6g-(4) 1105.0 726.7 1.521 1.00 1.67 600 587 4.9% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 60.0 3.83 0.230 1.5 ~12 
alkyne (5g) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 250 0.20 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
23.1 0.111 55% 480 
y = 0.6572x
R² = 0.9999
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Note: cell suspension (OD600 = 20) was added in three portions (20 mL each portion) every 
2 hours. 
 
1H NMR (400 MHz, CDCl3) δ 6.33 (d, J = 1.4 Hz, 1H), 4.12 (qd, 
J = 7.1, 3.3 Hz, 2H), 2.38 (d, J = 7.2 Hz, 2H), 2.10 (d, J = 1.6 Hz, 
1H), 1.82 – 1.52 (m, 6H), 1.27 – 1.07 (m, 6H), 0.98 (qt, J = 13.6, 
3.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 176.76, 114.74, 
94.58, 60.28, 36.22, 33.18, 33.17, 32.68, 26.41, 26.27, 26.25, 19.93, 14.53. HRMS (FAB) 
m/z: 209.1537 (M + H+); calc. for C13H21O2: 209.1542. [α]23D = + 53.4 ± 1.5° (c 0.1, 
cyclohexane). HPLC Chiralpak IC column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr 
= 7.59 min (major), 8.16 min (minor), 93.1:6.1 er. 
 
Ethyl (R)-2-(6-((tetrahydro-2H-pyran-4-yl)methoxy)hexyl)cycloprop-2-ene-1-
carboxylate (6h) 
GC calibration curve:  
 
 
Analysis data (10 mM 5h, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6h-(1) 40106 4085 9.818 7.31 1.77 4137   
6h-(2) 40775 4175 9.766 7.28 1.77 4115   
6h-(3) 39655 4125 9.613 7.16 1.77 4051   
6h-(4) 38780 4188 9.260 6.90 1.77 3902 4051 71.6% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
10 70.0 1.27 0.0886 3.0 ~10 
alkyne (5h) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 400 0.40 1.0 1.20 1.20 
y = 0.7452x
R² = 0.9975
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purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
81.3 0.262 66% 2960 
 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 200 4.84 0.968 12.0 ~11 
alkyne (5h) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 1.50 3.0 2.0 4.50 9.0 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
872.4 2.81 94% 2900 
Note: in 3.0-mmol scale reaction, EDA stock solution was added in three portions (1.5 mL 
each portion) every 1 hour. 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.4 Hz, 1H), 4.13 
(qd, J = 7.1, 5.5 Hz, 2H), 4.00 – 3.91 (m, 2H), 3.44 – 3.34 
(m, 4H), 3.24 (d, J = 6.6 Hz, 2H), 2.49 (td, J = 7.3, 1.4 Hz, 
2H), 2.12 (d, J = 1.5 Hz, 1H), 1.83 (ttt, J = 10.5, 6.7, 3.8 Hz, 
1H), 1.67 – 1.62 (m, 2H), 1.60 – 1.52 (m, 4H), 1.43 – 1.34 (m, 4H), 1.34 – 1.28 (m, 2H), 
1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.78, 115.66, 94.15, 76.12, 
71.25, 67.90, 60.32, 35.61, 30.19, 29.73, 29.11, 26.77, 26.02, 25.06, 19.86, 14.54. HRMS 
(FAB) m/z: 311.2210 (M + H+); calc. for C18H31O4: 311.2222. [α]23D = + 74.9 ± 1.8° (c 
0.1, cyclohexane). HPLC Chiralpak IC column (n-hexane/isopropanol = 88:12, 1.0 
mL/min), tr = 17.27 min (major), 20.55 min (minor), 99.0:1.0 er. 
 
Ethyl (R)-2-(6-(cyclopropylmethoxy)hexyl)cycloprop-2-ene-1-carboxylate (6i) 
GC calibration curve:  
 
 
Analysis data (10 mM 5i, P411-C6): 
y = 0.6917x
R² = 0.9998
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Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6i-(1) 26575 4144 6.413 4.44 2.01 2207   
6i-(2) 26599 4150 6.409 4.43 2.01 2206   
6i-(3) 26021 4086 6.368 4.40 2.01 2191   
6i-(4) 26300 4154 6.331 4.38 2.01 2179 2196 44.1% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
32 25.0 6.48 0.162 1.5 ~11 
alkyne (5i) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 1.0 900 0.90 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
61.8 0.232 64% 1430 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.5 Hz, 1H), 4.12 
(qd, J = 7.1, 5.2 Hz, 2H), 3.42 (t, J = 6.7 Hz, 2H), 3.24 (d, J = 
6.9 Hz, 2H), 2.49 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 
1H), 1.62 – 1.54 (m, 4H), 1.41 – 1.34 (m, 4H), 1.25 (t, J = 7.2 
Hz, 3H), 1.12 – 0.97 (m, 1H), 0.59 – 0.42 (m, 2H), 0.28 – 0.09 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 176.78, 115.68, 94.13, 75.74, 70.78, 60.31, 29.79, 29.11, 26.76, 26.04, 
25.05, 19.86, 14.54, 10.82, 3.13. HRMS (FAB) m/z: 267.1955 (M + H+); calc. for 
C16H27O3: 267.1960. [α]23D = + 43.1 ± 1.5° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 14.19 min (major), 15.27 min 
(minor), 95.8:4.2 er. 
 
Ethyl (R or S)-2-([1,1'-bi(cyclopropan)])-2-ene-1-carboxylate (R or S-6j) 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 25.0 4.47 0.112 1.2 ~11 
alkyne (5j) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 250 0.10 400 375 0.15 
purification eluent product 
Ether in pentane 
(0% to 20% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
10.7 0.0703 70% 630 
 
E. coli suspension expressing P411-K10 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 25.0 3.07 0.0767 1.2 ~11 
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alkyne (5j) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 250 0.10 400 375 0.15 
purification eluent product 
Ether in pentane 
(0% to 20% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
11.2 0.0736 74% 960 
 
1H NMR (600 MHz, Acetone-d6) δ 6.47 (d, J = 1.6 Hz, 1H), 4.13 – 4.03 
(m, 2H), 1.99 (d, J = 1.5 Hz, 1H), 1.91 (tt, J = 7.9, 4.6 Hz, 1H), 1.22 (t, 
J = 7.1 Hz, 3H), 1.01 – 0.94 (m, 2H), 0.84 – 0.80 (m, 1H), 0.61 – 0.58 
(m, 1H). 13C NMR (151 MHz, acetone) δ 175.54, 117.94, 92.45, 59.99, 
18.65, 14.46, 6.79, 6.05, 5.78. HRMS (EI) m/z: 152.0865 (M+∙); calc. for C9H12O2: 
152.0837. P411-C6: HPLC Chiralpak IC column (n-hexane/isopropanol = 95:5, 1.0 
mL/min), tr = 11.33 min (major), 11.79 min (minor), 93.4:6.6 er.  P411-K10: HPLC 
Chiralpak IC column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 11.33 min (minor), 
11.74 min (major), 66.7:33.3 er. 
 
Ethyl (R)-2-(4-chlorobutyl)cycloprop-2-ene-1-carboxylate (6k) 
GC calibration curve:  
 
 
Analysis data (10 mM 5k, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6k-(1) 322.4 517.1 0.623 0.56 1.82 308   
6k-(2) 363.5 517.4 0.703 0.63 1.82 347   
6k-(3) 342.8 523.4 0.655 0.59 1.82 324 326 6.0% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.27 0.251 2.0 ~12 
y = 0.9015x
R² = 0.9998
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alkyne (5k) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
800 125 0.10 800 375 0.30 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
17.6 0.0868 87% 340 
 
1H NMR (400 MHz, CDCl3) δ 6.37 (s, 1H), 4.12 (dd, J = 7.1, 4.2 Hz, 
2H), 3.54 (t, J = 6.5 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 2.13 (s, 1H), 
1.91 – 1.80 (m, 2H), 1.80 – 1.70 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.54, 114.98, 94.94, 60.37, 44.67, 
31.89, 24.39, 24.12, 19.83, 14.49. HRMS (FAB) m/z: 203.0846 (M + H+); calc. for 
C10H16ClO2: 203.0839. [α]23D = + 25.7 ± 1.6° (c 0.1, cyclohexane). HPLC Chiralpak IC 
column (n-hexane/isopropanol = 95:5, 1.0 mL/min), tr = 11.00 min (major), 12.62 min 
(minor), 94.2:5.8 er. 
 
Ethyl (R)-2-(6-((trans-4-(methoxymethyl)cyclohexyl)methoxy)hexyl)cycloprop-2-ene-
1-carboxylate (6l) 
GC calibration curve:  
 
 
Analysis data (10 mM 5l, P411-C6): 
Pdt- 
entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6l-(1) 14861 4259 3.489 2.41 1.93 1252   
6l-(2) 13735 4274 3.214 2.22 1.93 1153   
6l-(3) 16271 4222 3.854 2.66 1.93 1383   
6l-(4) 13204 4323 3.054 2.11 1.93 1096 1221 23.5% 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
y = 0.6913x
R² = 0.9998
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10 70.0 1.27 0.0886 3.0 ~10 
alkyne (5l) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 180 0.18 1.0 540 0.54 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
22.1 0.0627 35% 710 
Note: cell suspension (OD600 = 10) was added in two portions (35 mL each portion) every 
2 hours. 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.4 Hz, 
1H), 4.12 (qd, J = 7.1, 5.4 Hz, 2H), 3.37 (t, J = 6.6 
Hz, 2H), 3.32 (s, 3H), 3.21 – 3.17 (m, 4H), 2.49 (td, 
J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 1H), 1.87 – 
1.74 (m, 4H), 1.63 – 1.52 (m, 6H), 1.37 (tt, J = 6.3, 3.3 Hz, 4H), 1.25 (t, J = 7.1 Hz, 3H), 
0.99 – 0.86 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 176.79, 115.69, 94.12, 78.93, 76.90, 
71.17, 60.31, 58.98, 38.37 (two carbons), 29.74, 29.65, 29.55, 29.11, 26.77, 26.03, 25.06, 
19.86, 14.54. HRMS (FAB) m/z: 353.2699 (M + H+); calc. for C21H37O4: 353.2692. [α]23D 
= + 62.6 ± 2.7° (c 0.1, cyclohexane). HPLC Chiralpak IC column (n-hexane/isopropanol = 
93:7, 1.0 mL/min), tr = 10.07 min (major), 11.44 min (minor), 96.4:3.6 er. 
 
Ethyl (R)-2-(6-hydroxyhexyl)cycloprop-2-ene-1-carboxylate (6m) 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.80 0.272 1.5 ~12 
alkyne (5m) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 250 0.25 2.0 750 1.50 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
38.2 0.193 80% 710 
 
1H NMR (400 MHz, Acetone-d6) δ 6.56 (dt, J = 1.5 Hz, 1H), 4.05 
(qd, J = 7.1, 2.5 Hz, 2H), 3.52 (t, J = 6.2 Hz, 2H), 2.50 (tt, J = 7.1, 
1.6 Hz, 2H), 2.03 (d, J = 1.6 Hz, 1H), 1.63 – 1.56 (m, 2H), 1.55 – 
1.49 (m, 2H), 1.48 – 1.40 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H) (O‒H 
proton is not resolved). 13C NMR (101 MHz, Acetone-d6) δ 176.12, 116.11, 94.99, 62.12, 
60.23, 33.34, 27.33, 26.16, 25.47, 19.98, 14.72. HRMS (FAB) m/z: 199.1342 (M + H+); 
calc. for C11H19O3: 199.1334. [α]23D = + 80.1 ± 3.4° (c 0.1, ethyl acetate). HPLC Chiralpak 
IC column (n-hexane/isopropanol = 88:12, 1.0 mL/min), tr = 15.76 min (major), 16.86 min 
(minor), 96.0:4.0 er. 
 
Notes for other substrates: 
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During the test of analytical reactions, aliphatic alkynes 5n‒5q also gave a fair amount of 
cyclopropene products, which was detected by GC-MS. But making the racemic standards 
with Rh2(OAc)4 was problematic, resulting in no product formation or products with other 
impurities. 
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X. Derivatization of Bicyclobutane and Cyclopropene Products 
 
Diethyl (2R,4R)-1-(4-(1-((4-acetamidophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)phenyl) 
bicyclo[1.1.0]butane-2,4-dicarboxylate (4a) 
 
Bicyclobutane 2l (41.6 mg, 0.139 mmol) was dissolved in toluene 
(3 mL) in a 20 mL vial. Copper(I) thiophene-2-carboxylate (CuTc, 
3.2 mg, 12 mol%) was added. The mixture was kept stirring at 0 
°C. A suspension of 4-acetamidobenzenesulfonyl azide (40.2 mg, 
0.167 mmol) in toluene (5 mL) was added dropwise over 1 h. The 
resulting mixture was then allowed to warm to room temperature 
and stirred for 15 h. The reaction was diluted with ethyl acetate 
(15 mL), washed with NH4Cl/NH3 (2:1, 20 mL, aq.), and brine (50 
mL), dried over MgSO4, and then concentrated under reduced 
pressure. The crude product was purified by silica column chromatography with hexane / 
ethyl acetate (4:1 to 1:3 gradient) to afford 4a (69.2 mg, 0.129 mmol, 93%). 1H NMR (400 
MHz, CDCl3) δ 8.32 (s, 1H), 8.10 (s, 1H), 8.00 (d, J = 9.0 Hz, 2H), 7.74 (dd, J = 12.8, 8.7 
Hz, 4H), 7.34 (d, J = 8.6 Hz, 2H), 4.15 (dq, J = 7.1, 3.5 Hz, 2H), 4.08 (q, J = 7.1 Hz, 2H), 
3.28 (d, J = 0.6 Hz, 1H), 3.19 (dd, J = 3.1, 0.6 Hz, 1H), 3.14 (d, J = 3.1 Hz, 1H), 2.20 (s, 
3H), 1.27 (t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.14, 169.15, 167.88, 147.11, 145.13, 134.03, 130.40, 129.53, 128.96, 127.92, 126.19, 
119.62, 119.22, 61.17, 61.13, 44.75, 42.63, 27.84, 24.93, 21.39, 14.35, 14.21. HRMS 
(FAB) m/z: 539.1605 (M + H+); calc. for C26H27O7SN4: 539.1600. [α]23D = ‒81.5 ± 2.1° (c 
0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-(1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-
4-yl)phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (4b) 
 
Sodium azide (7.02 g, 108 mmol) was dissolved in a mixture of 
water (30 mL) and DCM (15 mL) at 0 °C. Triflic anhydride (Tf2O, 
3 mL, 18 mmol) was added dropwise over 10 min. The reaction 
was then stirred for 2 h. The reaction was diluted with DCM (15 
mL), washed by NaHCO3 (50 mL, sat. aq.), and brine (50 mL), and 
dried over Na2SO4. A solution of triflic azide (TfN3, ~15 mmol) in 
DCM was used for the next step. 
Methyl L-phenylalaninate hydrochloride (1.73 g, 8.0 
mmol), was dissolved in MeOH (16 mL). A aqueous solution of 
CuSO4 (1.28 mL, 10 g/L, 1 mol%) and N,N-diisopropylethylamine 
(DIPEA, 2.09 mL, 12.0 mmol) were added. The resulting solution was stirred for 30 min 
before the dropwise addition of triflic azide (TfN3, ~15 mmol in DCM) over 20 min. The 
reaction was stirred for 15 h. The reaction mixture was diluted with DCM (40 mL), washed 
by water (50 mL), HCl (50 mL, 5%, aq.), NaHCO3 (50 mL, sat. aq.), and brine (50 mL), 
and dried over Na2SO4. After evaporation of solvent under reduced pressure, the product 
mixture was purified by silica column chromatography with hexane / ethyl acetate (1:0 to 
12:1 gradient) to afford methyl (S)-2-azido-3-phenylpropanoate (1.65 g, 8.0 mmol, 
quantitative). 
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Bicyclobutane 2l (49.5 mg, 0.166 mmol) was dissolved in THF/H2O (1:1, 1.6 mL) 
in a 20 mL vial. A aqueous solution of CuSO4 (17 μL, 1N, 10 mol%) and Cu powder (10.6 
mg, 0.166 mmol) were added. The mixture was kept stirring at 0 °C. A solution of methyl 
(S)-2-azido-3-phenylpropanoate (50.1 mg, 0.249 mmol) in THF (0.5 mL) was added 
dropwise over 5 min. The resulting mixture was then allowed to warm to room temperature 
and stirred for 24 h. The reaction was diluted with DCM (15 mL), washed with NH4Cl (10 
mL, aq. sat.), and brine (30 mL), dried over MgSO4, and then concentrated under reduced 
pressure. The crude product was purified by silica column chromatography with hexane / 
ethyl acetate (8:1 to 2:1 gradient) to afford 4b (82.5 mg, 0.164 mmol, 99%) as one major 
diastereomer determined by 1H NMR. 1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 7.78 – 
7.69 (m, 2H), 7.37 – 7.30 (m, 2H), 7.28 – 7.20 (m, 3H), 7.08 – 7.03 (m, 2H), 5.63 (dd, J = 
8.1, 6.7 Hz, 1H), 4.15 (qd, J = 7.1, 2.6 Hz, 2H), 4.08 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 3.52 
(dd, J = 7.4, 3.2 Hz, 2H), 3.28 (d, J = 0.5 Hz, 1H), 3.17 (dd, J = 3.1, 0.6 Hz, 1H), 3.13 (d, 
J = 3.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.24, 168.84, 167.87, 147.40, 134.77, 132.77, 129.67, 129.08, 128.98, 128.84, 
127.77, 125.80, 119.75, 64.17, 61.05, 61.01, 53.26, 44.71, 42.64, 39.12, 27.99, 20.89, 
14.36, 14.22. HRMS (FAB) m/z: 504.2148 (M + H+); calc. for C28H30O6N3: 504.2135. 
[α]23D = ‒278.7 ± 4.0° (c 0.0625, ethyl acetate). 
 
Note: A diastereomer of 4b was prepared through the same procedure using D-azido-
phenylalanine. It was confirmed that the pair of diastereomers can be resolved on 1H NMR 
at the α-C‒H position of phenylalanine (splitting peaks: D-phenylalanine: 5.6410, 5.6242, 
5.6208, 5.6041; L-phenylalanine: 5.6462, 5.6296, 5.6261, 5.6093; FWHM (full width at 
half maxima) = 0.0030 ppm; Δf1 = 0.0053 ppm, close to baseline separation). 
 
Diethyl (2R,4R)-1-(4-((((R)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoyl)oxy) 
methyl)phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (4c) 
 
Bicyclobutane 2m (16.1 mg, 0.053 mmol) and (R)-3,3,3-trifluoro-2-
methoxy-2-phenylpropanoic acid (R-Mosher’s acid, 30.4 mg, 0.13 
mmol) were dissolved in dry DCM (2 mL) in a 10 mL vial. 1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 24.9 
mg, 0.13 mmol), triethylamine (TEA, 18 μL, 0.13 mmol) and 4-
dimethylaminopyridine (DMAP, 2.0 mg, 0.015 mmol) were added 
to the solution. The reaction mixture was then stirred at room 
temperature for 16 h. The reaction was diluted with DCM (5 mL), 
washed with water (10 mL), and brine (10 mL), dried over MgSO4, 
and then concentrated under reduced pressure. The crude product was purified by silica 
column chromatography with hexane / ethyl acetate (1:0 to 4:1 gradient) to afford 4c (25.2 
mg, 0.048 mmol, 91%) as one major diastereomer determined by 1H NMR. 1H NMR (400 
MHz, CDCl3) δ 7.48 – 7.41 (m, 2H), 7.41 – 7.32 (m, 3H), 7.27 (s, 4H), 5.33 (d, J = 12.3 
Hz, 1H), 5.29 (d, J = 12.2 Hz, 1H), 4.15 (qd, J = 7.2, 2.6 Hz, 2H), 4.07 (qd, J = 7.2, 2.0 
Hz, 2H), 3.51 (q, JH-F = 1.2 Hz, 3H), 3.26 (d, J = 0.6 Hz, 1H), 3.14 (dd, J = 3.1, 0.6 Hz, 
1H), 3.11 (d, J = 3.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.01, 167.67, 166.43, 133.67, 133.32, 132.11, 129.64, 128.54, 
128.53, 128.42, 127.54, 127.28, 127.27, 124.68, 121.81, 118.94, 84.75, 67.60, 60.96, 
  
57 
 
60.88, 55.54, 44.61, 42.44, 27.66, 20.85, 14.23, 14.03 (CF3, 127.54, 124.68, 121.81, 
118.94, JC-F = 288.8 Hz; ). HRMS (FAB) m/z: 519.1651 ((M + H+) ‒ H2); calc. for 
C27H26O7F3: 519.1631. [α]23D = ‒43.2 ± 2.4° (c 0.1, ethyl acetate).  
 
Note: A diastereomer of 4c was prepared through the same procedure using S-Mosher’s 
acid. It was confirmed that the pair of diastereomers can be resolved on 1H NMR at one 
benzylic C‒H position and 19F NMR, albeit not perfectly (splitting peaks on 1H NMR: R-
Mosher’s acid: 5.3027, 5.2721; S-Mosher’s acid: 5.3044, 5.2737; FWHM = 0.0024‒0.0029 
ppm  ppm; Δf1 = 0.0017 ppm; chemical shift on 19F NMR: R-Mosher’s acid: ‒71.665; S-
Mosher’s acid: ‒71.654; FWHM = 0.015 ppm  ppm; Δf1 = 0.011 ppm). 
 
((1R,2R)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2,4-diyl)dimethanol (4d) 
 
Bicyclobutane 2k (101.3 mg, 0.33 mmol) was dissolved in anhydrous 
ether (10 mL) in a 50 mL flask. Dry methanol (67 μL, 1.67 mmol) was 
added to the solution, followed by the addition of lithium borohydride 
(LiBH4, 2M in THF, 0.84 mL, 1.67 mmol). The reaction mixture was 
then heated up to a refluxing temperature, 45 °C, for 1 h, before ethyl 
acetate (0.5 mL) was added and the mixture was stirred at room 
temperature for 30 min. Then the reaction was quenched with NH4Cl 
(10 mL, sat. aq.) and diluted with water (10 mL). The product was 
extracted with ethyl acetate (20 mL × 6). The combined organic layer was dried over 
MgSO4, and then concentrated under reduced pressure. White solid product crashed out 
during the removal of solvent. Collecting the solid product and recrystallization with 
acetone/hexane system afforded the diol 4d (52.2 mg, 0.237 mmol, 71%). 1H NMR (400 
MHz, Acetone-d6) δ 7.31 (d, J = 8.9 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H), 3.71 
– 3.65 (m, 1H), 3.65 – 3.61 (m, 1H), 3.57 – 3.51 (m, 1H), 3.49 – 3.43 (m, 2H), 2.28 (t, J = 
5.8 Hz, 1H), 1.92 (dd, J = 3.6, 1.0 Hz, 1H) (O‒H protons are not resolved). 13C NMR (101 
MHz, Acetone) δ 158.07, 129.14, 129.08, 113.58, 60.27, 60.14 (splitting), 55.88, 55.75 
(splitting), 54.56, 49.65, 49.61 (splitting), 46.08, 46.04 (splitting), 21.53, 16.55. (Note: the 
diol product might have two rotating conformations, resulting in splitting of 4 carbon 
peaks.) HRMS (FAB) m/z: 221.1168 (M + H+); calc. for C13H17O3: 221.1178. [α]23D = ‒
50.8 ± 1.2° (c 0.1, acetone). 
 
Crystal structure information of 3d: 
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Identification code  p17505 
Empirical formula  C13 H16 O3 
Formula weight  220.26 
Temperature  175 K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 1 21 1 
Unit cell dimensions a = 5.3738(7) Å a= 90° 
 b = 7.6719(8) Å b= 98.413(9)° 
 c = 13.7357(19) Å g = 90° 
Volume 560.19(12) Å3 
Z 2 
Density (calculated) 1.306 Mg/m3 
Absorption coefficient 0.747 mm
‒1
 
F(000) 236 
Crystal size 0.22 x 0.18 x 0.06 mm3 
Theta range for data collection 3.252 to 79.483°. 
Index ranges ‒6<=h<=6, ‒9<=k<=9, ‒16<=l<=17 
Reflections collected 17841 
Independent reflections 2338 [R(int) = 0.0437] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.8812 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2338 / 1 / 148 
Goodness-of-fit on F2 1.111 
Final R indices [I>2sigma(I)] R1 = 0.0471, wR2 = 0.1225 
R indices (all data) R1 = 0.0482, wR2 = 0.1232 
Absolute structure parameter 0.15(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.337 and ‒0.270 e.Å‒3 
 
Ethyl (1R,2R)-4-(hydroxymethyl)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2-
carboxylate (4e) 
 
Mono-alcohol 4e was obtained from the reduction of bicyclobutane 
2k. Collecting the mother liquor after recrystallization, evaporation of 
organic solvent followed by purification by silica column 
chromatography with hexane / ethyl acetate (5:1 to 3:1 gradient) 
afforded 4e (14.6 mg, 0.056 mmol, 17%) with ~7:1 r.r. determined by 
1H NMR. 1H NMR (400 MHz, Acetonitrile-d3) δ 7.20 (d, J = 8.8 Hz, 
2H), 6.88 (d, J = 8.8 Hz, 2H), 4.05 (qd, J = 7.1, 0.5 Hz, 2H), 3.78 (s, 
3H), 3.43 (t, J = 6.3 Hz, 2H), 2.75 (tdd, J = 7.0, 3.3, 0.7 Hz, 1H), 2.70 (t, J = 5.9 Hz, 1H), 
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2.68 (s, 1H), 2.64 (d, J = 3.3 Hz, 1H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CD3CN) δ 168.54, 159.04, 129.70, 127.38, 114.20, 60.92, 56.42, 55.44, 47.23, 42.52, 
24.86, 18.43, 13.99. MS (EI) m/z: 262 (M+∙); calc. for C15H18O4: 262. 
 
(2-(4-Methoxyphenyl)cyclobut-1-ene-1,3-diyl)dimethanol (4f) 
 
Bicyclobutane 2k (54.7 mg, 0.18 mmol) was dissolved in 
anhydrous ether (5 mL) in a 20 mL vial and then cooled down to 
‒78 °C. Lithium aluminium hydride (LAH, 13.7 mg, 0.36 mmol) 
was slowly added to the solution in portions. The reaction 
mixture was slowly warmed up to ‒20 °C over 2 h, before ethyl 
acetate (0.5 mL) was added and the mixture was stirred at ‒20 °C for another 30 min. Then 
the reaction was quenched with NH4Cl (10 mL, sat. aq.) and diluted with water (10 mL). 
The product was extracted with ethyl acetate (20 mL × 3). The combined organic layer was 
dried over MgSO4, and then concentrated under reduced pressure. The crude product was 
purified by silica column chromatography with hexane / ethyl acetate (2:1 to 1:2 gradient) 
to afford 4f (18.1 mg, 0.082 mmol, 46%). 1H NMR (400 MHz, Acetonitrile-d3) δ 7.34 (d, 
J = 8.8 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 4.30 (d, J = 3.1 Hz, 2H), 3.80 (s, 5H), 3.57 (ddd, 
J = 11.2, 7.2, 4.3 Hz, 1H), 3.21 – 3.12 (m, 1H), 2.95 (t, J = 5.7 Hz, 1H), 2.70 (t, J = 5.5 Hz, 
1H), 2.59 (dd, J = 13.7, 4.6 Hz, 1H). 13C NMR (101 MHz, CD3CN) δ 159.59, 140.27, 
140.19, 128.91, 128.55, 114.63, 65.02, 59.23, 55.79, 42.11, 31.40. MS (EI) m/z: 220 (M+∙); 
calc. for C13H16O3: 220. 
 
Diethyl (2R,4R)-1-(4-(((4-(4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl)benzoyl)oxy) 
methyl)phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (4g) 
 
Tetrachlorophthalic anhydride (14.30 g, 50.0 mmol) and 4-
aminobenzoic acid (6.86 g, 50.0 mmol) were dissolved in PhMe 
(100 mL) to form a suspension. The mixture was heated up to 
110 °C and stirred vigorously, before the addition of TEA (0.35 
mL, 5 mol%). The reaction turned clear and then white product 
started to crash out. The reaction was stirred at the refluxing 
temperature for 1 h, and then slowly cooled to room 
temperature. The product 4-(4,5,6,7-tetrachloro-1,3-
dioxoisoindolin-2-yl)benzoic acid (20.05 g, 49.5 mmol, 99%) 
was collected by filtration.  
      4-(4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl)benzoic 
acid (40.5 mg, 0.1 mmol) and DMF (3 drops, cat.) was dissolved 
in dry DCM (8 mL) and SOCl2 (2 mL). The mixture was heated 
and stirred at a refluxing temperature, 48 °C for 4 h. After completely removing organic 
solvent and excess SOCl2 under reduced pressure, the resulting crude product 4-(4,5,6,7-
tetrachloro-1,3-dioxoisoindolin-2-yl)benzoyl chloride was dissolved in dry DCM (3 mL) 
and used directly for next step. 
Bicyclobutane 2m (15.2 mg, 0.050 mmol) and TEA (14 μL, 0.10 mmol) were 
dissolved in dry DCM (2 mL) in a 10 mL vial. The solution of prepared benzoyl chloride 
in DCM was added to the solution. The reaction mixture was then stirred at room 
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temperature for 12 h. The reaction was diluted with DCM (5 mL), washed with water (10 
mL), and brine (10 mL), dried over MgSO4, and then concentrated under reduced pressure. 
The crude product was purified by silica column chromatography with hexane / ethyl 
acetate (1:0 to 4:1 gradient) to afford 4g (30.0 mg, 0.0434 mmol, 87%) as a white solid. 1H 
NMR (400 MHz, Acetonitrile-d3) δ 8.21 (d, J = 8.6 Hz, 2H), 7.60 (d, J = 8.7 Hz, 2H), 7.47 
(d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 5.38 (s, 2H), 4.09 (dq, J = 14.2, 7.1 Hz, 4H), 
3.30 (dd, J = 3.1, 0.6 Hz, 1H), 3.16 (d, J = 3.1 Hz, 1H), 3.07 (d, J = 0.5 Hz, 1H), 1.23 (t, J 
= 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CD3CN) δ 170.14, 167.93, 
165.82, 163.12 (two carbons), 140.42, 136.05, 135.95, 133.64, 130.76, 130.67, 130.00, 
128.81, 128.72, 128.55, 127.57, 66.99, 61.30, 61.25, 45.10, 42.39, 27.43, 21.38, 14.04, 
13.92. HRMS (ESI) m/z: 712.0082 (M + Na+); calc. for C32H23Cl4NO8Na: 712.0075. [α]23D 
= ‒48.5 ± 1.6° (c 0.1, acetone). 
 
Ethyl (1R,2R,3S)-3-allyl-2-methyl-2-phenethylcyclopropane-1-carboxylate (7a) 
Cyclopropene (R)-6a (54.0 mg, 0.25 mmol) and CuI (5.0 mg, 0.026 
mmol, 10 mol%) were dissolved in anhydrous ether (3 mL) to form 
a suspension in a 25 mL flask. Then the flask was charged with 
argon and cooled to ‒78 °C. Methylmagnesium bromide (0.75 mL, 
1M in ether, diluted from 3M solution in ether) was added 
dropwise to the reaction mixture over 10 min. The reaction was slowly warmed to ‒40 °C 
over 30 min and held at this temperature for another 1 h. A solution of allyl bromide (43 
μL, 0.50 mmol) in ether (1 mL) was then added to the reaction dropwise over 5 min. The 
reaction was stirred at ‒40 °C for 1 h, before it was quenched with NH4Cl/NH3 (2:1, aq., 5 
mL) at ‒20 °C. The aqueous layer was extracted twice with ether. The combined organic 
layers were washed with water (10 mL), and brine (10 mL), dried over MgSO4, and then 
concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane / ethyl acetate (1:0 to 50:1 gradient) to afford 7a (48.0 mg, 
0.176 mmol, 71%) as a single diastereomer. 1H NMR (400 MHz, CDCl3) δ 7.23 – 7.17 (m, 
2H), 7.13 – 7.07 (m, 3H), 5.73 (ddt, J = 17.3, 10.2, 6.2 Hz, 1H), 4.97 (dq, J = 17.2, 1.7 Hz, 
1H), 4.89 (ddt, J = 10.2, 2.0, 1.4 Hz, 1H), 4.07 – 3.96 (m, 2H), 2.68 – 2.60 (m, 2H), 2.33 
(ddt, J = 7.6, 6.2, 1.5 Hz, 2H), 1.57 – 1.51 (m, 2H), 1.40 (d, J = 8.9 Hz, 1H), 1.23 (s, 3H), 
1.18 (t, J = 7.1 Hz, 3H), 1.09 (dt, J = 8.8, 7.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
171.68, 142.04, 137.72, 128.38, 128.33, 125.81, 114.58, 59.80, 45.06, 32.87, 31.77, 29.13, 
27.89, 27.34, 14.39, 11.53. HRMS (FAB) m/z: 273.1849 (M + H+); calc. for C18H25O2: 
273.1855. [α]23D = ‒61.3 ± 1.7° (c 0.1, ethyl acetate). 
 
Ethyl (1R,6R,7R)-3,4-dimethyl-1-(6-((tetrahydro-2H-pyran-4-yl)methoxy)hexyl) 
bicyclo[4.1.0]hept-3-ene-7-carboxylate (7b) 
 
Cyclopropene (R)-6g (65.6 mg, 0.211 mmol) was 
dissolved 2,3-dimethylbutadiene (0.5 mL). Then the 
reaction was heated and stirred at 80 °C in a sealed tube 
for 23 h. After cooling to room temperature, the resulting 
mixture was concentrated under reduced pressure. The crude product was purified by silica 
column chromatography with hexane / ethyl acetate (1:0 to 6:1 gradient) to afford 7b (81.1 
mg, 0.207 mmol, 98%) as a single diastereomer. 1H NMR (400 MHz, CDCl3) δ 4.09 (qd, 
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J = 7.1, 0.4 Hz, 2H), 4.01 – 3.90 (m, 2H), 3.45 – 3.32 (m, 4H), 3.24 (d, J = 6.6 Hz, 2H), 
2.43 – 2.29 (m, 1H), 2.30 – 2.09 (m, 3H), 1.90 – 1.75 (m, 1H), 1.67 – 1.60 (m, 4H), 1.58 – 
1.50 (m, 10H), 1.46 – 1.38 (m, 1H), 1.36 – 1.26 (m, 5H), 1.26 – 1.15 (m, 5H). 13C NMR 
(101 MHz, CDCl3) δ 173.76, 122.00, 121.77, 76.09, 71.37, 67.91, 60.21, 35.85, 35.60, 
32.93, 32.16, 30.85, 30.20, 29.80, 29.69, 27.92, 26.89, 26.86, 26.33, 19.30, 19.09, 14.55. 
HRMS (FAB) m/z: 393.2992 (M + H+); calc. for C24H41O4: 393.3005. [α]23D = ‒48.2 ± 1.1° 
(c 0.1, ethyl acetate). 
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XI. Chiral HPLC Traces for Racemic and Enzymatically Synthesized Cyclopropene 
Products  
All the ee values of enzymatically synthesized cyclopropene products were 
determined using chiral HPLC. The chiral HPLC traces for racemic and enzymatic 
products are shown below.  
The absolute configuration of enzymatically synthesized cyclopropene product 6b 
was determined to be (R) by comparing the chiral GC separation of rac-6b and 6b with 
that reported in the literature (16) (and confirmed by comparing the optical rotation 
numbers of 6b and (S)-6b with literature values). The absolute configurations of other 
cyclopropene products were inferred by analogy, assuming the selectivity with the same 
P411 variant remains the same in the biosyntheses of compound 6a‒6m.  
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac-, R- and S-6a:  
rac-6a R-6a 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
8.820 5105.03 50.19 9.057 7330.2 99.95 
9.144 5066.41 49.81 9.416 4.4 0.05 
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Total 10171.44 100.00 Total 7334.6 100.00 
S-6a 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
8.893 48.5 0.45 
9.200 10437.1 99.55 
Total 10485.6 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
GC (γ-TA column): 110 ºC (the third trace) 
 
 
Area% report for rac- and R-6b:  
rac-6b R-6b 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
6.475 4707.7 49.89 6.594 5043.93 98.02 
6.927 4729.1 50.11 7.099 102.06 1.98 
  
64 
 
Total 9436.8 100.00 Total 5145.99 100.00 
R-6b (chiral GC) 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
74.972 2240.08 98.34 
76.195 37.88 1.66 
Total 2277.96 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac- and R-6c:  
rac-6c R-6c 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
10.347 6143.95 49.77 10.367 8079.11 98.00 
11.454 6201.66 50.23 11.547 165.21 2.00 
Total 12345.61 100.00 Total 8244.32 100.00 
 
 
Chiralpak IC, 9% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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Area% report for rac- and R-6d:  
rac-6d R-6d 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
17.027 6378.13 49.91 17.055 7518.01 95.28 
18.715 6401.27 50.09 19.063 372.37 4.72 
Total 12779.4 100.00 Total 7890.38 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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Area% report for rac- and R-6e:  
rac-6e R-6e 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
15.335 4382.18 50.47 15.031 17990.7 96.81 
16.815 4300.19 49.53 16.922 592.4 3.19 
Total 8682.37 100.00 Total 18583.1 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac- and R-6f:  
rac-6f R-6f 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
9.414 4415.92 50.11 9.419 4104.93 97.27 
10.871 4396.46 49.89 10.917 115.14 2.73 
Total 8812.38 100.00 Total 4220.07 100.00 
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Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
 
Area% report for rac- and R-6g:  
rac-6g R-6g 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
7.550 5484.74 49.83 7.127 7090.46 93.05 
8.102 5522.14 50.17 7.563 529.64 6.95 
Total 11006.88 100.00 Total 7620.10 100.00 
 
 
Chiralpak IC, 12% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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Area% report for rac- and R-6h:  
rac-6h R-6h 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
17.527 2944.10 50.03 17.272 1166.58 98.95 
20.370 2940.07 49.97 20.548 12.34 1.05 
Total 5884.17 100.00 Total 1178.92 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac- and R-6i:  
rac-6i R-6i 
Retention Area Area % Retention Area Area % 
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Time (min) (mAU*s) Time (min) (mAU*s) 
14.107 7660.01 49.18 14.192 8396.37 95.83 
14.954 7914.53 50.82 15.257 365.59 4.17 
Total 15574.54 100.00 Total 8761.96 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac- and R-6j:  
S-6j R-6j 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
11.327 10039.7 33.26 11.325 11590.7 93.43 
11.739 20144.1 66.73 11.791 814.5 6.57 
Total 30183.8 100.00 Total 12405.2 100.00 
 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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Area% report for rac- and R-6k:  
rac-6k R-6k 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
10.944 6736.15 49.72 10.970 9049.69 94.15 
12.452 6811.65 50.28 12.610 562.69 5.85 
Total 13547.8 100.00 Total 9612.38 100.00 
 
 
Chiralpak IC, 7% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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Area% report for rac- and R-6l:  
rac-6l R-6l 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
Retention 
Time (min) 
Area 
(mAU*s) 
Area % 
10.132 11165.0 49.76 10.065 16783.3 96.39 
11.214 11274.8 50.24 11.435 628.6 3.61 
Total 22439.8 100.00 Total 17411.9 100.00 
 
 
Chiralpak IC, 12% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
Area% report for rac- and R-6m:  
rac-6m R-6m 
Retention Area Area % Retention Area Area % 
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Time (min) (mAU*s) Time (min) (mAU*s) 
15.695 8828.78 49.97 15.760 8045.71 96.00 
16.614 8838.24 50.03 16.860 335.20 4.00 
Total 17667.02 100.00 Total 8380.91 100.00 
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XII. NMR Spectra  
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